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Abstract
This thesis addresses some of the challenges that clinicians face in the course of treatment
of brain tumors. Glioblastoma multiforme (GBM, grade IV) is the most malignant form
of primary brain tumor and recurrence following treatment is common. Non-invasive
imaging is an important component of brain tumor treatment planning and monitoring.
Unfortunately, tumor recurrence and radiation injury (RI) in patients with GBM have
similar appearances on follow-up conventional magnetic resonance imaging (MRI),
making it difficult to choose the most appropriate treatment plan. Brain metastases which
are secondary brain tumors are common in patients with systemic cancer. Differentiating
between GBM and metastatic tumor is also difficult with conventional MRI, but is
essential for guiding surgical and radiotherapy treatment. Therefore, the overall goal of
this thesis is to develop imaging methods that improve brain tumor detection.
The first objective was to develop a method to discriminate between GBM tumor
recurrences and RI using a multiparametric characterization of the tissue incorporating
conventional MRI signal intensities (T2-weighted (T2w) and fluid attenuated inversion
recovery (FLAIR)) and diffusion tensor imaging parameters (fractional anisotropy (FA)
and radial diffusivity (RD)). In the RI region there were significant correlations between
FA and RD as well as between T2w and FLAIR signal intensities. No such correlations
were observed in the tumor region. These correlations may aid in differentiating between
tumor recurrence and RI.
The second objective was to differentiate between GBM and metastasis (MET); the two
most common types of brain tumors. Both exhibit similar radiologic appearance on
ii

routine MR imaging but require different treatment strategies. The goal of this study
was to investigate whether texture based image analysis of routine MR images (contrastenhanced T1-weighted images) would provide quantitative information that could be
used to differentiate between GBM and MET. Our results demonstrate that first-order
texture feature of standard deviation and second-order texture features of entropy, inertia,
homogeneity, and energy show significant differences between the two groups. Receiver
operating characteristic (ROC) curve analysis showed that combining first- and secondorder features increased the predictive accuracy in differentiating between GBM and
MET.
Finally, helical tomotherapy (HT) is a type of radiation delivery technique that allows for
a radiosurgery-type simultaneous infield boost (SIB) of multiple brain metastases,
synchronously with whole brain radiation therapy (WBRT). However, some patients’
tumors may not respond to HT type WBRT+SIB. The goal of our study was to
investigate whether quantitative measurements of tumor size and appearance on magnetic
resonance imaging (MRI) scans acquired prior to HT type WBRT+SIB treatment could
be used to differentiate responder and non-responder patient groups. Our results
demonstrated that smaller size lesions may respond better to this type of radiation
therapy. Measures of appearance provided limited added value over measures of size for
response prediction. Quantitative measurements of rim enhancement and core necrosis
performed separately did not provide additional predictive value.
In summary, our correlation based method for differentiating tumor from RI,
differentiating GBM and MET using quantitative texture features, and correctly selecting
iii

patients who will respond to HT type radiation treatment may be used to better plan
patient treatment.

Keywords
Glioblastoma, multiparametric imaging, CT perfusion, diffusion tensor imaging, MRI,
metastasis, helical tomotherapy, whole brain radiotherapy. Stereotactic radiosurgery,
texture analysis, RECIST, entropy, homogeneity, correlation, inertia, energy.
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Introduction

Accurate discrimination of tumor from radiation injured tissues and differentiation of
tumor types and grades using noninvasive imaging is essential for guiding surgical and
radiotherapy treatments. This thesis describes the use of multiparametric imaging and
image processing techniques to characterize brain tumors. The long-term goal of these
methods is to help select appropriate treatment and assess treatment response in patients
with brain tumor.
This chapter introduces the imaging and image processing techniques upon which the
following chapters are based. Chapter 2 describes the application of multiparametric
imaging in an attempt to improve the detection of brain tumor recurrence following
treatment. Chapter 3 describes the use of texture based analysis in differentiating
enhancing lesions as primary or secondary tumor types. Chapter 4 outlines the use of
texture based image analysis for patient selection in radiation therapy.

1.1

Brain Tumor

A tumor is any uncontrolled growth of abnormal cells. Tumors that are located within the
brain are called brain tumors and can be classified into two categories: primary and
secondary brain tumors.
Primary brain tumors can arise from the cells, the meninges (membranes around the
brain), or neurons in the brain. Gliomas and meningiomas are the most common primary
1

brain tumors. Gliomas are thought to be derived from glial cells such as astrocytes,
oligodendrocytes, and ependymal cells. Gliomas are classified into four grades by the
World Health Organization (WHO) on the basis of their histologic features and
malignancies1. Glioblastomas are considered grade IV; the most aggressive and
malignant type of brain tumor.
Secondary brain tumors are referred to as metastases. They do not initiate in the brain,
but rather metastases occurs when cancer cells break away from a primary tumor site
elsewhere in the body and travel to the brain through the blood system.

1.1.1

Primary Brain Tumor: Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most lethal and aggressive form of primary brain
tumor. It is a grade IV type of brain tumor. Median survival for patients with
glioblastoma is 12-15 months2. GBM is derived from the malignant transformation of
glial cells3. Despite recent advances in radiation, chemotherapy, surgical techniques, and
newer investigational drugs, GBM has a poor prognosis. Medical imaging plays an
important role in the diagnosis of GBM. Typically post-contrast magnetic resonance
(MR) imaging is used for diagnosis followed by biopsy for pathological validation. GBM
often appear as ring-enhancing lesions on post-contrast MR images (Figure 1.1)3, 4.
Treatment options for patients with GBM are determined by tumor size, location, and the
associated symptoms. The current standard of care for patients with GBM is surgical
resection of the tumor followed by radiation therapy and concomitant and adjuvant
temozolomide chemotherapy. This approach has been shown to standardize treatment and
prolong survival for patients5. Radiation therapy damages the genetic material (DNA)
2

within tumor cells and limits their ability to successfully reproduce6, 7. Tumor cells are
less able to repair DNA than healthy cells. With each subsequent radiation dose, the
cumulative effect of unrepaired DNA strand breaks initiates apoptosis (cell death) in
these tumor cells6, 7.
Radiation injury (RI) is an undesirable but unavoidable side effect of radiation treatment.
Radiation injury is characterized by extensive necrosis due to small artery injury and
direct damage to oligodendroglia8. The incidence of radiation injury depends on the total
radiation dose and the rate of delivery9. Concomitant chemotherapy enhances radiation
injury. RI appears as enhancing lesions on MR imaging. Since GBM is a high grade
tumor, recurrences are common even after treatment, and these recurrences appear as
hyperintense regions on post-contrast MR images.

Figure 1.1 Post-contrast T1-weighted image of patient with glioblastoma. The tumor
appears to have a necrotic core and enhancing rim.
The presence of enhancing lesions after chemo-radiation therapy may represent either
tumor recurrence or radiation induced injury or both 10, 11. Differentiating between tumor
recurrence and RI regions can be difficult with conventional MR imaging 12, however it
3

is very important to differentiate these two entities since the treatment options and
prognoses for each are considerably different.
There have been numerous attempts to differentiate tumor recurrences from RI using
conventional morphologic imaging as well as various functional imaging techniques such
as CT perfusion, MR perfusion, diffusion weighted imaging, MR spectroscopy, singlephoton emission computed tomography and positron emission tomography12-29. Table 1.1
provides a partial list of studies that have used various techniques to differentiate tumor
recurrence from RI.
Table 1.1 Techniques used for differentiating tumor recurrence from radiation
injury12-29
Technique
Diffusion

Reference
Hein et al.
Kashirmura et al.
Asai et al.
Sundgren et al.
Xu et al.
Zeng et al.

Parameter
Apparent diffusion coefficient ratios
Fractional anisotropy
Apparent diffusion coefficient
Fractional anisotropy
Fractional anisotropy
Apparent diffusion coefficient

Perfusion

Barajas et al.
Jain et al.
Jain et al.
Bobek-Billewicz
Fisher-stevens et al.

Cerebral blood volume
Cerebral blood flow
Cerebral blood volume
Cerebral blood volume
Permeability

MRS

Rabinov et al.
Zeng et al.
Zeng et al.
Rock et al.
Rock et al.

Choline / Creatine
Choline / Creatine
Choline / N-Acetyl aspartate
Choline / Creatine
Choline / N-Acetyl aspartate

PET

Langleben et al.
Tsuyuguchi et al.

Fluorodeoxy glucose uptake
11
C-Methionine uptake

SPECT

Schwartz et al.
Samnick et al.

201Thallium uptake
123 Iodine uptake
4

All of the above techniques have shown some promise but none of them have been able
to convincingly differentiate radiation injury from tumor recurrence. FDG-PET and
dynamic contrast enhanced CT have shown better sensitivity and accuracy compared to
other techniques. However, with the limited availability of PET scanners and the risks
associated with radiation exposure from CT, the search for an accessible and reliable
technique continues with biopsy of the affected tissue still considered the gold standard.

1.1.2

Secondary Brain Tumor: Metastasis

Brain metastasis is common among patients with systemic cancer. They are a significant
public health issue, with 20–40% of patients with solid tumors subsequently developing
symptomatic brain metastases30. Approximately 150,000 brain metastases are diagnosed
annually in the United States. Brain metastasis (MET) is thought to occur when the
primary tumor acquires the ability to migrate away from the primary site and travels to
the brain. The most common origins of brain metastasis are from breast cancer,
melanoma and lung cancer. Metastasis often causes severe neurological symptoms that
significantly impair quality of life. With recent improvements in diagnostic imaging and
increasing patient survival due to improved systemic cancer control, the incidence of
intracranial metastatic disease is projected to rise31. Imaging is the most important
diagnostic modality for brain metastasis. Metastasis appears as an enhancing rim with
necrotic core on a post-contrast MRI (Figure 1.2). The management of brain metastasis
initially involves treating the symptoms using corticosteroids, anticonvulsants to reduce
peritumoral edema and prevent recurrent seizures and surgical resection for debulking
5

followed by therapeutic approaches of whole brain radiotherapy (WBRT), stereotactic
radiosurgery (SRS), and/or chemotherapy.

Figure 1.2 Post-contrast T1-weighted image of patient with metastasis. The tumor
has a necrotic core and enhancing rim.

Whole brain radiotherapy (WBRT) is the most commonly used treatment for patients
with brain metastasis. It involves delivering a uniform dose of radiation from a linear
accelerator to the entire brain while the patient head is immobilized to minimize
movement during treatment32. A perforated thermoplastic mask that is shaped to conform
to the individual patient’s facial features is used to immobilize the patient’s head during
treatment. Whole brain radiation therapy (WBRT) delivers an even dose of radiation to
the entire brain. Figure 1.3 shows WBRT radiation dose planning image. It can be used to
treat small undetectable tumors, large tumors that may be developing in different areas of
the brain and tumors that are deep in the brain which are inaccessible to surgery. Since
radiation is delivered to the entire brain WBRT has side effects that include nausea,
vomiting, headache, fever, fatigue and possible worsening of neurologic symptoms.
6

There is also a risk of memory loss or dementia. WBRT typically improves symptoms,
but longer-term survivors may develop neurocognitive deficits33, 34.

Figure 1.3 Radiation dose planning image for WBRT (yellow=100% of the dose,
orange =98%, red=95%, green = 80%, blue =70%). A traditional WBRT delivers
30-60 Gy in 10-15 fractions.

Stereotactic radiosurgery (SRS) is a more targeted form of radiation therapy in which a
higher dose of radiation is delivered to the tumor in a single treatment session. Figure 1.4
shows a typical SRS radiation dose planning image. The radiation beam is concentrated
on a small region of the parietal lobe. Typically multiple radiation beams are delivered to
7

the tumor from many different angles using special computer planning. A stereotactic
head frame is used to keep the patient’s head completely still during the procedure.
Because this form of radiation targets the tumor more precisely, it is less likely to hurt
healthy tissue. Generally, SRS may be used to treat patients with up to three lesions,
although this may vary depending on the size and location of the tumors. For multiple
lesions (>3), WBRT is usually the best option. WBRT or SRS is also an option for people
who are not candidates for surgery.

Figure 1.4 Radiation dose planning image for SRS (yellow=100% of the dose,
orange =98%, red=95%, green = 80%, blue =70%). A traditional SRS would deliver
15-20 Gy in a single fraction.

8

SRS combined with WBRT has been shown to yield superior local control, as compared
with WBRT alone35. Since SRS involves high dose of radiation to a small region, it has a
higher frequency of side effects related to brain tissue necrosis and edema, which can put
pressure on surrounding healthy brain tissue. SRS also requires separate stereotactic
localization and treatment procedures that add to the cost and patient inconvenience. In
addition, the sequential delivery of WBRT and SRS does not allow for the integration of
radiation delivery across both components, limiting the ability to fully optimize the
radiation dose.
Helical tomotherapy (HT) is a radiotherapy delivery technique that allow for
radiosurgery-type simultaneous infield boost (SIB) treatments to be given synchronously
with the standard WBRT dose. In HT, the treatment beam rotates about the gantry while
the patient table is moved through the gantry, thereby creating a helical or spiral type of
beam, hence the name helical tomotherapy. This form of delivery technique can be used
to efficiently boost multiple brain metastases without the need for separate stereotactic
procedures36,

37

. The ability to incorporate this boost contribution with larger field

volumes as part of the treatment planning optimization process is advantageous over
sequential WBRT and SRS. It has also been shown that HT type WBRT+SIB dose
distribution and lesion conformity is comparable to SRS alone38. This type of radiation
delivery is beneficial for patients with multiple lesions and lesions that are in close
proximity to sensitive organs. It is also useful for patients who cannot be immobilized
due to claustrophobia, obesity or physical impairment39.

9

Figure 1.5 Radiation dose planning image for HT, illustrating a whole brain
radiation plan with integrated high-dose boost (purple) to a metastatic lesion. The
patient underwent HT with 30 Gy WBRT and 60 Gy SIB in 10 fractions.

HT type WBRT+SIB has potential advantages compared to surgery and SRS but it is not
appropriate for every patient. Some patients’ tumors may not respond to simultaneous
WBRT+SIB, and are more appropriately treated with radiosurgery or conventional
surgery.

1.2

Treatment Assessment

Treatment assessment is critical for measuring tumor response to therapy. The
development of contrast-enhanced CT and MR imaging has allowed radiologists to assess
therapeutic response more accurately and reproducibly in patients with brain tumors.
Imaging for treatment assessment is routinely performed at three months interval post
chemo-radiation therapy. Advanced CT and MRI techniques are currently being used in
research settings as response assessment tools for brain tumor patients and are based on
detecting cellular changes, and detecting changes in metabolic and hemodynamic
10

activity40. In clinical settings, changes in lesion size are widely used to assess tumor
response to therapy.

1.2.1

Response Evaluation Criteria in Solid Tumors

The assessment of treatment response in brain tumors is based on clinical and imaging
parameters. A number of techniques have been proposed to assess treatment response.
The Macdonald criteria are widely used in assessing treatment response41 of glial tumors.
These criteria involve computing the cross-sectional area of the tumor by measuring the
longest single diameter and the longest perpendicular diameter. A 50% decrease in the
area is considered a partial response while an 25% increase in the area is considered
progression. As an update to the Macdonald criteria, the revised assessment in neurooncology criteria42 is used for assessing disease progression and treatment response in
GBM.
The most common way to assess treatment response in metastasis is the anatomical based
method known as response evaluation criteria in solid tumors (RECIST). RECIST were
originally published in 2000 and then updated in 2009 for use as a treatment assessment
tool in clinical oncology43,

44

. RECIST are a set of guidelines that were developed to

allow for a simplified and standardized assessment of solid tumors. They classify
therapeutic responses in brain tumors based on a one-dimensional tumor measurement:
the longest diameter across a contrast-enhancing lesion in the axial plane. In cases where
multiple lesions are present, the sum of the longest diameters of up to two measurable
lesions is obtained.

11

Table 1.2 Four categories of RECIST.
Response

Criteria: Description

RECIST 1.1
Complete
Response Disappearance of all target lesions.
(CR)
At least a 30% decrease in the sum of
Partial Response (PR)
diameters of the target lesions, taking as reference the
baseline sum diameters.
Progressive
(PD)

Disease At least a 20% increase in the sum
of diameters of target lesions, taking as reference
the baseline sum diameters. The appearance of one or
more new lesions is also considered progression.

Stable Disease (STD)

Neither sufficient shrinkage to qualify as PR nor
sufficient progression to qualify as PD.

The major advantage of the RECIST system is its simplicity. A single diameter
measurement is done in the axial plane on the post-contrast images, which can be

performed easily and rapidly. The technique performs comparably to more complex
two-dimensional and volumetric methods of treatment assessment in brain tumor
studies45, 46.

1.3

Multiparametric Imaging

Imaging modalities such as computed tomography (CT) and magnetic resonance imaging
(MRI) are commonly used for diagnosis and treatment assessment. CT is often the first
line imaging modality performed in patients with brain tumors because it is relatively
inexpensive, minimally invasive, and widely available in clinical settings. CT is also used
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for surgical planning and radiation treatment planning but MRI is preferred due to its
superior soft tissue contrast. For brain tumors, imaging is routinely performed before the
initial treatment, immediately after the treatment and at 3-6 month interval thereafter (for
high grade brain tumor patients imaging is performed at 2-3 months intervals).
RECIST measures tumor response to treatment based on assessment of anatomical MR
images. RECIST requires a well-defined anatomical lesion and relies on the serial
measurements of reduction in tumor size during treatment as the basis for response
assessment. Treatment selection and response assessment can also be based on functional
evaluation of CT and MR images.

1.3.1

Perfusion CT

Brain tumors are associated with angiogenesis and neovascularization (forming new
blood vessels) that results in increased blood volume and permeability related to the
immature vessels47-51. Previous studies have indicated increased microvascular
permeability with the increase in biologic aggressiveness of tumors, while a reduction in
permeability in response to therapy correlates with decreased tumor growth49, 50. Since
perfusion CT (PCT) provides an in vivo marker of angiogenesis, it is widely used as both
a diagnostic tool and as a treatment assessment tool in brain tumor imaging52, 53.
Perfusion CT typically requires the acquisition of a baseline image without contrast
enhancement followed by a series of images acquired as a function of time following an
intravenous bolus injection of a conventional iodinated CT contrast material. The
resulting temporal changes in contrast enhancement of the tissue are displayed as time–
13

attenuation curves (TAC). These TACs are used to quantify a range of parameters that
reflect the functional status of the vascular system. This approach is used to produce
parametric maps that represent cerebral blood volume (CBV), blood flow (CBF),
permeability (PS), mean transit time (MTT), and the size of extravascular space. Many of
these parameters have been correlated with tumor grade, aggressiveness, and
prognosis54, 55.
Tissue perfusion, blood volume, mean transit time, and other vascular physiological
parameters can be derived from dynamic CT data53, 56. The first phase of enhancement
(Figure 1.6) can be used to evaluate blood flow, and blood volume which are generally
increased in malignant tissues. The second phase is used to evaluate vascular
permeability (since tumor blood vessels are abnormally permeable to the contrast agent
used)56,

57

.

Deconvolution method is the most widely used analysis method for

determination of perfusion parameters. The deconvolution operation uses a reference
“arterial” input function that is selected most often within the anterior cerebral artery. The
impulse residue function (IRF) is then calculated by deconvolution of the arterial and
tissue time–attenuation curves for the tissue of interest. The IRF (Figure 1.7) is usually
constrained in its shape to comprise a plateau followed by a single exponential decay53.
The height of the flow scaled IRF will provide the cerebral blood flow and the area under
the curve will determine the cerebral blood volume. Width of the IRF equals the mean
transit time (MTT). This approach can also be used to include a measurement of capillary
permeability by use of a distributed parameter model53.
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Figure 1.6 A general arterial time attenuation curve showing the first and second
phase enhancement. (HU = hounsfield units).

Figure 1.7 Blood flow scaled IRF according to the Johnson and Wilson model. The
height of the IRF is the cerebral blood flow and the area under the curve will
determine the cerebral blood volume. Width of the IRF equals the mean transit
time.
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PCT provides quantitatively accurate assessment of brain perfusion. PCT measurements
have been shown to be reproducible and have been validated against a range of reference
methods including xenon CT and positron emission tomography (PET)58-64. PCT has
been used to estimate tumor grade and predict response to radiation therapy in cerebral
tumors65-67. The results of perfusion studies49, 50 have shown that CBV and PS, a measure
of microvascular permeability, are predictive of pathologic grade and correlates with
tumor activity. Studies utilizing perfusion techniques have used cerebral blood volume
(CBV) values68-70 and recovered percentage of signal intensity and peak height71 (i.e.
shape of dynamic perfusion data) to differentiate between metastasis and GBM.

1.3.2

MRI: T1w, T2w and FLAIR Imaging72, 73, 74

MR imaging is an important diagnostic and treatment assessment imaging modality that
has become essential to routine clinical brain tumor imaging due to its superior soft tissue
contrast. In clinical MR imaging, the hydrogen nucleus (proton) is primarily used because
it is abundantly present in the human body (70-90%) and has high detection sensitivity
due to its high gyromagnetic ratio. Since hydrogen atoms have an odd number of protons,
this nucleus possesses a property known as spin angular momentum. The phenomenon of
magnetic resonance arises in atoms with odd numbers of protons. In absence of a static
magnetic field, the protons are oriented randomly and the net macroscopic magnetic
moment is zero. When these protons are subjected to a static magnetic field (B0), the
magnetic moment vectors have a tendency to align in the direction of the static field
producing a net magnetization (M0). They also exhibit precessional behavior at a welldefined frequency due to the interaction between the static magnetic field and the
16

magnetic moment of the nucleus. The frequency of precession is proportional to the
strength of the static magnetic field and is expressed by the Larmor Equation (equation
1.1).
𝑓=

𝛾

2𝜋

𝐵0

[1.1]

f = Larmor frequency in Hertz
B0 = static magnetic field strength in Tesla (T)

γ = gyromagnetic ratio (for protons, γ = 42.57 MHz/T)

In order to induce signal in the tissue of interest, a component of the net magnetization
must be tilted away from its equilibrium axis (z-axis) into the transverse (x-y) plane,
which is achieved by applying a rotating magnetic field in the transverse plane at the
Larmor frequency using a radio frequency (RF) coil. This process is called excitation,
and the applied magnetic field is called an RF pulse. The amplitude and duration of this
RF pulse produces a predictable torque on the magnetization vector causing it to rotate
away from its equilibrium position by precessing about the axis defined by the RF pulse.
This angle of rotation away from the z-axis is also known as flip angle. The transverse
component of the magnetization is then detected by the same RF coil. The resulting timevarying signal is called the free induction decay (FID) and represents the basic MR
signal. The most common excitation RF pulse is a 90o pulse that rotates the
magnetization by 90o into the x-y plane resulting in no z-component. Eventually the net
magnetization vector will return to its equilibrium state along the z-axis: this process is
called relaxation. Relaxation has both longitudinal and transverse components that occur
simultaneously but independent of each other. Longitudinal relaxation refers to recovery
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of the longitudinal magnetization along the z-axis, and is characterized by the T1 time
constant (Figure 1.8). This is the mechanism by which protons give up their energy to the
surrounding lattice in order to return to their equilibrium energy distribution. This process
of relaxation is also known as spin-lattice relaxation.
The longitudinal component of magnetization can be written as:
−𝑡

𝑀𝑧 (𝑡) = 𝑀0 (1 − 𝑒 𝑇1 )

[1.2]

Figure 1.8 T1 relaxation curve showing recovery from Mz = 0 following a 90o pulse.

Figure 1.8 shows the T1 relaxation curve. There is no longitudinal magnetization
following the 90o RF pulse. Longitudinal magnetization is generated as protons release
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their energy to the lattice. This regeneration of the longitudinal magnetization follows an
exponential growth process characterized by the T1 time constant.
Transverse relaxation describes the loss of phase coherence of the magnetization in the
transverse plane and is characterized by the T2 time constant (Figure 1.9). One
mechanism that leads to the decay of transverse magnetization is when protons exchange
energy amongst themselves (spin-spin interactions) resulting random phase following
energy transfer. This process is also known as spin-spin relaxation.
The transverse component of magnetization can be written as:
−𝑡

𝑀𝑥𝑦 (𝑡) = 𝑀0 (𝑒 𝑇2 )

[1.3]

Figure 1.9 T2 signal decay in the transverse plane following excitation. The Blue
line represents a long T2 decay while the orange line represents a short T2 decay.
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Figure 1.9 shows the T2 decay curve. Following a 90o RF pulse, the magnetic moments
of protons have a transverse orientation and rotate together (in-phase) around the
magnetic field axis. After a short period of time due to spin-spin interactions, the
directions of the protons begin to spread (dephase) causing the transverse magnetization
to decay.
During relaxation of the longitudinal magnetization, individual tissues have different
levels of magnetization due to their inherently unique T1 values. Similarly, during decay
of the transverse magnetization, individual tissues have different levels of magnetization
due to of their unique T2 values. These T1 and T2 relaxation time constants are intrinsic
features of the underlying tissue and vary according to tissue type.
MR images are made up of thousands of tiny squares known as pixels (picture element)
or voxels (volume elements). The signal intensity in the pixel or voxel represents the MR
signal arising from a volume of tissue that is excited. The greater the MR signal from that
tissue, the higher will be the signal intensity of that voxel. Various tissues have different
signal intensities on MR image. The differences of the signal intensity are described as
image contrast and it allows us to see the boundaries between the tissues. T1 and T2
values of the tissue are important factors that determine the image contrast. MR imaging
allows us to produce a wide range of contrasts by changing the acquisition parameters of
the MRI pulse sequence.
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The MRI pulse sequence represents a precisely timed series of RF and gradient pulses.
Gradient pulses create linear variations in the static magnetic field strength and are used
to produce a spatially localized signal. Figure 1.10 shows one cycle of a hypothetical
MRI pulse sequence. The repetition time (TR) is defined as the time from the center of
the first RF pulse to the center of the first RF pulse in the next repetition of the sequence.
The time at which the signal is measured is the echo time (TE). TE is defined as the time
between the center of the first RF pulse and the center of the echo.

Figure 1.10 A simplified spin echo sequence (phase and frequency encoding gradients
not shown here).

By varying the TR and TE, image contrast can be manipulated. Varying the TR modifies
the amount of T1 weighting while varying the TE modifies the amount of T2 weighting
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in an image. The ability to modify image contrast gives MRI tremendous flexibility. The
most common pulse sequences used to create contrast in MR imaging are “spin echo”,
“gradient echo”, and “inversion recovery” sequences.

Spin echo: A basic spin echo pulse sequence consists of two RF pulses (Figure 1.10). The
first RF pulse is a 90o pulse that excites the protons and produces a FID, and the second
RF pulse is an 180o pulse that refocuses the transverse magnetization so that the
dephasing effects resulting from B0 inhomogeneities can be removed. This 180° pulse is
exactly halfway between the excitation pulse and the echo. It is also known as a
refocusing pulse since it flips the protons around an axis in the transverse plane. The
phase that the spins accumulated during the first half of the TE interval is then reversed
during the second half of the TE interval and the spin echo is formed.
Gradient echo: A basic gradient echo sequence (GRE) uses a single RF pulse with a flip
angle (α) of less than 90o. The echo is generated by gradient reversal (Figure 1.11). GRE
are a class of imaging sequences that do not use an 180o RF pulse to refocus the
transverse magnetization. The absence of the 180o refocusing pulse allows for faster
imaging, but makes it sensitive to the effects of B0 inhomogeneities.

22

Figure 1.11 Gradient echo sequence.
T1-weighted and T2-weighted images can be produced with either spin echo or gradient
echo sequences. T1w images rely on relatively short values of TR to produce T1weighting and very short TE values to eliminate T2-weighting. T2w images rely on very
long values of TR to eliminate T1-weighting and long TE values to produce T2weighting by creating differences in transverse magnetization between tissue types.
Inversion recovery: Inversion recovery is a variant of a spin echo or gradient echo
sequence. The only difference is an additional 180o inversion pulse that is applied before
the excitation pulse. Following the inversion pulse and before the excitation pulse there is
a delay (known as the inversion time). This inversion time provides a mechanism to use
differences in T1 relaxation to generate contrast between tissues of interest. One of the
most common variants of the inversion recovery sequence is the fluid attenuated
inversion recovery (FLAIR). In a FLAIR sequence, the inversion time is chosen to
correspond to the zero-crossing point (Figure 1.12) in the T1 relaxation curve of fluid,
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specifically cerebrospinal fluid (CSF). With signal from CSF nulled, lesions in the brain
parenchyma appear brighter.

Figure 1.12 Inversion recovery sequence.

In routine brain tumor imaging, morphological MR images are usually acquired as preand post-contrast T1w images, T2w images, and FLAIR images. Contrast agents are
pharmaceuticals which are used to improve diagnostic information by changing the signal
intensity differences. They change the intrinsic tissue properties by changing the local
magnetic field and consequently the T1 and T2 relaxation times. Along with CT, MRI is
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the first line of diagnostic imaging performed for patients with symptoms suggesting
brain tumor. T1w images best depict the anatomy of the brain, and, when used with a
contrast agent they also may show brain pathology. However, T2-weighted images
provide the best depiction of the tumor, because most tissues that are involved in a
pathologic process have higher water content than the normal brain matter, and the fluid
causes the affected areas to appear bright on T2w images.
Most brain tumors have prolonged T1 and T2 relaxation times and will appear
hypointense relative to normal brain tissue on a T1w image and hyperintense on a T2w
image. However, the presence of hemorrhage, necrosis, or calcification can cause a
heterogeneous appearance of the tumor. On a post-contrast T1-weighted image, the
contrast (gadolinium) accumulates in the extracellular space of the tumor due to local
disruption of the blood-brain barrier. As a result, the tumor appears brighter than the
normal brain tissue on a post-contrast T1-weighted image due to shortening of the T1
relaxation time constant.
Morphological MRI is helpful in diagnosis of brain tumors, however morphologic MRI
alone is insufficient for grading malignant brain tumors, differentiating between tumor
types, or differentiating between tumor recurrence and radiation necrosis75. Additional
imaging techniques have been developed to overcome this problem. Tumors can be
further characterized by using advanced MRI techniques such as diffusion tensor
imaging, dynamic contrast-enhanced MRI, perfusion MRI and MR spectroscopy76-79.
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1.3.3

Diffusion Tensor Imaging

Diffusion Tensor Imaging (DTI) is an advanced MRI technique that provides information
about the diffusivity of water molecules in the tissue and that can be used to map fiber
tracts in the brain80, 81, 82. DTI is non-invasive. It utilizes existing MRI technology and
does not require the administration of a contrast agent. This technique exploits the
sensitivity of MRI to random water diffusion in the brain tissue in the presence of
diffusion gradient pulses that are incorporated into the MR imaging pulse sequence.
To understand diffusion it is important to understand the concept of ‘phase’. Consider
three sine waves (Figure 1.13) that are oscillating at the same rate but two of them are
shifted along the x-axis. It can be said that the sine waves have the same frequency but
different phase. Phase describes the instantaneous position of the sine wave within the
cyclic variation. Similarly, phase in MRI refers to an angle and describes the position of
the protons relative to each other. Immediately after the first 900 RF pulse, all the protons
precess synchronously, they have a phase difference of 0o and are said to be in-phase
(phase coherence). Due to T2 relaxation and susceptibility differences within tissue
leading to magnetic field inhomogeneities, the phase coherence disappears and the
protons are said to be out of phase (dephased). Figure 1.13 (a) shows the protons with
same phase and (b) different phase.

26

(a)

(b)

Figure 1.13 Sine waves and protons with (a) same phase and (b) different phase.

In DTI imaging, the 90° RF pulse generates a transverse magnetization that is purposely
dephased by the application of a large diffusion gradient. If no diffusion is present, the
protons do not move, and a second diffusion gradient is designed to rephase the
magnetization completely. However, if diffusion occurs, the protons change their spatial
position, and the second gradient does not perfectly rephase the magnetization. Since the
gradients are controlled by the MRI pulse sequence, information about the diffusion
process can be inferred by measuring the signal with (M) and without (M0) diffusion
gradients. Figure 1.14 below shows a basic spin echo MRI pulse sequence with the
addition of diffusion gradients.
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Figure 1.14 DTI sequence: spin echo sequence with the addition of diffusion
gradients.

Diffusion in the anisotropic white matter is modeled as a second-order tensor (Figure
1.15). To quantify the second-order tensor, measurements are made in at least six noncollinear directions.
The diffusion tensor is calculated for each pixel according to the following equation83, 84.

𝑀

𝑀0

= exp(− ∑6𝑖=1 ∑6𝑗=1 𝑏𝑖𝑗 𝐷𝑖𝑗 )

[1.4]

𝐷𝑖𝑗 are elements of the diffusion tensor matrix

𝜕

𝑏𝑖𝑗 are elements of the b matrix and is calculated as 𝑏𝑖𝑗 = 𝛾 2 𝜕 2 𝐺𝑖 𝐺𝑗 (∆ − )
3

where i, j = x, y, z
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The tensor can be diagonalized to obtain its eigenvalues (λ1, λ2, λ3). The corresponding
directions of these eigenvalues are the eigenvectors (e1, e2, e3). The eigenvectors
represent the tensors principle coordinate, and the eigenvalues describes the shape and
size of the tensor. Figure 1.15 below shows the diffusion tensor with the eigenvalues.

Figure 1.15 Diffusion tensor with eigen values λ1, λ2, λ3. The diffusion is highly
anisotropic in fibrous tissues such as white matter, and the direction of largest
diffusivity is generally assumed to be parallel to the local direction of the white
matter.
The eigen value information from the diffusion tensor measurements are used to calculate
the following diffusion tensor parameters: mean diffusivity (MD), fractional anisotropy
(FA), axial diffusivity (AxD) and radial diffusivity (RD) as shown in the following
equations:
Mean Diffusivity (MD): The mean diffusivity is the average of the eigenvalues.
𝑀𝐷 = 𝜆̅ = (𝜆1 + 𝜆2 + 𝜆3)/3

[1.5]
29

Fractional Anisotropy (FA): The fractional anisotropy is the ratio of the anisotropic
component of the diffusion tensor to the whole diffusion tensor

���2 +(𝜆2−𝜆)
���2 + (𝜆3−𝜆)
���2

3
(𝜆1−𝜆)
𝐹𝐴 = � �

[1.6]

𝜆12 + 𝜆22 + 𝜆32

2

Axial Diffusivity (AxD): The axial diffusivity is the principal eigenvalue.
𝐴𝑥𝐷 = 𝜆1

[1.7]

Radial Diffusivity (RD): The radial diffusivity is the average of the radial eigenvalues.

𝑅𝐷 =

(𝜆2+ 𝜆3)

[1.8]

2

Table 1.3 Summary of the diffusion tensor parameters.
Diffusion
Tensor Formula
Parameters
𝜆1 + 𝜆2 + 𝜆3
Mean Diffusivity
3
Fractional
3 (𝜆1 − ���
𝜆)2 + (𝜆2 − ���
𝜆)2 + (𝜆3 − ���
𝜆)2
� �
Anisotropy
2
𝜆12 + 𝜆22 + 𝜆32
Axial Diffusivity
Radial Diffusivity

𝜆1

(𝜆2 + 𝜆3)
2

Description
Average of the eigen
values.
Ratio of the anisotropic
component
of
the
diffusion tensor to the
whole diffusion tensor.
Principal eigen value.
Average of the middle and
shorter eigen values.

Diffusion is considered isotropic when the eigenvalues are nearly equal. Conversely, the
diffusion tensor is anisotropic when the eigenvalues are significantly different in
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magnitude. The magnitudes of eigenvalues are affected by changes in local tissue
microstructure that occurs due to normal physiological changes (i.e. aging) and also by
different types of tissue injury or neurological diseases85, 86, 87. Therefore, the parameters
derived from the diffusion tensor may be a sensitive probe for characterizing both normal
and abnormal tissue microstructure.
There has been strong interest in exploring the clinical applications of DTI in the
assessment of brain tumors88-92. DTI has been used for tumor grading93 and tumor
delineation94. Functional diffusion maps have been used for early assessment of tumor
response to treatment95. DTI has also been used to differentiate between glioblastoma and
metastasis96. DTI studies have shown differences in DT parameters in GBM compared to
MET97. In some studies higher DT parameter values of FA, linear tensor (CL) and planar
tensor (CP) and lower values of spherical tensor (CS) were observed in GBM and were
useful for discriminating between the tumor types98-100.

1.4

Texture Analysis

Texture is an important characteristic of images and refers to the appearance of the
image. Image texture is a function of the spatial variation of pixel intensities in an
image101, 102. Image texture analysis can provide quantitative information in the form of
texture features that is not visible to human vision103. Texture features are mathematical
parameters computed from the distribution of pixels, which characterize the texture type
in the image. The most common method of computing the image texture is to use a
statistical based method that analyzes the properties of individual pixel intensities and
their spatial distribution within the image104.
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Statistical based texture analyses are commonly classified as first-order and secondorder textures, based on the number of pixels defining the local features. First-order
textures estimate properties of individual pixel values, ignoring the spatial interaction
between the neighboring image pixels, whereas second-order textures estimate properties
of two or more pixel values occurring at specific locations relative to each other.

1.4.1

First-Order Textures

Textures based on first order statistics are features that can be computed from the gray
level histogram. The histogram of an image is the count of the number of pixels in the
image that possess a given grey-level value. Figure 1.16 shows an example gray-level
histogram. The most common first-order texture features are the mean, standard
deviation, skewness and kurtosis.

Figure 1.16 Gray-level histogram.
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(1) Mean of the histogram is the mean of the gray-levels in an image.
𝑥̅ =

1

𝑛

∑𝑛𝑖=1 𝑥𝑖

[1.9]

x = gray levels
n = number of gray-levels
(2) Standard deviation is a measure of how far from the mean the gray values in the
image are distributed.

1

𝑠 = � ∑𝑛𝑖=1(𝑥𝑖 − 𝑥̅ )2

[1.10]

𝑛

(3) Skewness of the histogram refers to the asymmetry of the distribution of the gray
values 105. A distribution is symmetric if the right side of the distribution is similar to the
left side of the distribution. If the distribution is symmetric, then the skewness value is
zero. A distribution with an asymmetric tail extending out to the right is referred to as
positively skewed, while a distribution with an asymmetric tail extending out to the left is
referred to as negatively skewed.
The skewness of a distribution is defined as:

𝑠𝑘 =

1 𝑛
∑ (𝑥 −𝑥̅ )3
𝑛 𝑖=1 𝑖

1
(𝑥 −𝑥̅ )2
�� ∑𝑛
𝑛 𝑖=1 𝑖

[1.11]

3

�

(4) Kurtosis is a measure of how flat or peaked the top of a symmetric distribution is
when compared to a normal distribution. If the grey level distribution is similar to the
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normal distribution, the kurtosis value is 3. Flat-topped distributions are referred to as
platykurtic and have a kurtosis value of less than 3, while less flat-topped distributions
are referred to as leptokurtic and have a kurtosis value greater than 3.
The kurtosis of a distribution is defined as:

𝑘=

1 𝑛
∑ (𝑥 −𝑥̅ )4
𝑛 𝑖=1 𝑖
1
𝑛

[1.12]

4

2
�� ∑𝑛
𝑖=1(𝑥𝑖 −𝑥̅ ) �

The limitation of the histogram-based measurements is that they carry no information
regarding the relative spatial position of pixels with one another. The spatial relationship
of the pixels can be incorporated by taking in to account the distribution of intensities as
well as the position of pixels with equal or nearly equal intensity values. This can be
achieved by constructing a gray level co-occurrence matrix as explained in the next
section.

1.4.2

Second-Order Textures

Textures based on second-order statistics are features that can be computed from the gray
level co-occurrence matrix (GLCM). The GLCM is a two-dimensional histogram of graylevels for a pair of pixels separated by a fixed distance (d) at a fixed angle (θ)103. 104. It is
an estimate of the joint probability G(i, j) of the intensity values of two pixels (i and j), at
a certain pixel distance apart along a given direction (i.e., the probability that i and j have
the same intensity). This joint probability takes the form of a square matrix with row and
column dimensions equal to the number of discrete gray levels (intensities) in the image.
If an intensity image contained no texture (intensity variations) the resulting GLCM
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would be completely diagonal. As the image texture increases (i.e. as the local pixel
intensity variations increase), the off-diagonal values in the GLCM become larger.
GLCMs are usually computed with neighboring pixels defined in angular directions 0o,
45o, 90o and 135o.
Figure 1.17 shows an example to construct a GLCM. Consider a 4x4 image (Figure
1.17a) with 4 gray-levels from 0 to 3 (Figure 1.17b). A generalized GLCM is shown in
Figure 1.17c where (i, j) stands for the number of times gray-level i and j satisfy the
condition stated by the offset distance vector d and angle θ.
The resulting four GLCMs for d = [0 1] and [0 -1] and θ = 0o, 45o, 90o, 135o are shown in
Figure 1.17d-g.

Figure 1.17b Gray-levels in the

Figure 1.17a
1 a Sample
Sample
image.
image.

sample image.
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Figure 1.17c: general form of a GLCM
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Figure 1.17d: GLCM for θ = 0o

Figure 1.17e: GLCM for θ = 45o
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Figure 1.17d: GLCM for θ = 90o

Figure 1.17e: GLCM for θ = 135o

GLCMs as seen above are symmetric matrices. Hence either upper or lower triangle is
used for calculation of the second-order features. Each element in the GLCM is the
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probability of co-occurrence of the pixel gray-levels. The second-order texture features
can then be calculated using the formulas shown below.
Each of the five GLCM-based second-order texture features that are used in this thesis
are described below:
(1) Entropy is the measure of randomness of the GLCM. It describes the amount of chaos
or disorder within the elements of the GLCM. Entropy is higher when the image is nonuniform.
𝐸𝑛𝑡𝑟𝑜𝑝𝑦 = − ∑𝑖,𝑗 𝐺(𝑖, 𝑗) 𝑙𝑜𝑔2 𝐺(𝑖, 𝑗)

[1.13]

G(i, j) = probability of co- occurrence of the pixel gray-levels
(2) Homogeneity measures the closeness of the distribution of elements in the GLCM to
the GLCM diagonal. It is also known as inverse difference moment. It is sensitive to the
near diagonal elements of the GLCM. It is higher for a diagonal GLCM.
𝐻𝑜𝑚𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑦 = ∑𝑖,𝑗

1

1+|𝑖−𝑗|

𝐺(𝑖, 𝑗)

[1.14]

(3) Inertia measures the intensity or gray-level variation between the reference pixel and
its neighbor over the whole image. It describes the local variations in the GLCM. It is
inversely correlated to homogeneity and will be lower for a diagonal GLCM.
𝐼𝑛𝑒𝑟𝑡𝑖𝑎 = ∑𝑖,𝑗(𝑖 − 𝑗)2 𝐺(𝑖, 𝑗)

[1.15]
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(4) Correlation measures how correlated a reference pixel is to its neighbor over the
whole image. It describes the joint probability occurrence of the specified pixel pairs.
Correlation is 1 or -1 for a perfectly positively or negatively correlated image.
𝐶𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 = ∑𝑖,𝑗

(𝑖−𝜇)(𝑗−𝜇)𝐺(𝑖,𝑗)

[1.16]

𝜎2

𝜇 𝑎𝑛𝑑 𝜎 𝑎𝑟𝑒 𝑡ℎ𝑒 𝑚𝑒𝑎𝑛 𝑎𝑛𝑑 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛.
(5) Energy describes the uniformity of the image. It measures the sum of squared
elements of the GLCM. It is also known as angular second moment feature. Energy is
high if the image is homogenous.
𝐸𝑛𝑒𝑟𝑔𝑦 = ∑𝑖,𝑗 𝐺(𝑖, 𝑗)2

1.4.3

[1.17]

Texture Analysis of Medical Images

MR images hold a large amount of texture information that may be relevant for clinical
diagnosis. Due to its inherent resolution limitation, MR images are not capable of
providing microscopic tissue information that can be evaluated visually. However,
histological changes present in various diseases may generate textural changes in the MR
image that can be quantified through texture analysis.
Image texture analysis has been used in a range of MR studies for classifying tissues in
brain tumors. It has also been used to differentiate between different tumor grades106 and
discriminate between benign, malignant, and normal tissue types on MR images107.
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Texture analysis has been used to study the effects of traumatic brain injury on texture
features108. Genetic features have been discovered by texture analysis that could favor
prognosis in low grade oligodendroglioma109. Texture analysis has been used to segment
structures in the normal brain110, 111 as well as in epilepsy to identify abnormalities in the
hippocampus112 by detecting differences in the texture features.
Image texture analysis has been used in a range of CT and MRI studies for classifying
non- cerebral tissues. Texture analysis has been used on computed tomography (CT)
images to detect microcalcification in breast cancer113, microcalcification susceptibility
effects on breast MRI114, and to analyze breast tumors on contrast-enhanced MRI

115

.

Texture differences were observed in MR images of the spinal cord between normal
subjects and patients with relapsing multiple sclerosis before the atrophy was visually
detectable116.Texture analysis has also been successfully applied to the classification of
pathological tissues in the lungs117 and skeletal muscles118.
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1.5
1.5.1

Thesis Objectives
Objective 1: Multiparametric imaging in patients with
glioblastoma

Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor.
The current standard of care for patients with GBM is surgery followed by chemo- and
radiation therapy. Since GBM is a grade IV tumor, recurrences are common even after
the treatment. Radiation injury (RI), a side effect of radiation therapy and tumor
recurrences appears hyperintense on conventional MR images. Differentiating between
RI and tumor recurrences is important for treatment planning. Numerous techniques have
been utilized trying to find biomarkers for differentiation, however biopsy is still the gold
standard. The purpose of our current study was to determine whether a multiparametric
characterization of tissue based on correlations of T2w signal intensity, FLAIR signal
intensity, and diffusion tensor imaging parameters could differentiate RI from tumor
recurrence.

1.5.2

Objective 2: Texture analysis in differentiating between
glioblastoma and metastasis

Glioblastoma and metastasis are the two most common types of brain tumor. Both types
of tumors exhibit similar radiologic appearance on routine MR images. Differentiating
between GBM and MET is very important because they have different biological
mechanisms and require different treatment strategies. Previous studies have focused on
advanced imaging modalities, such as diffusion tensor imaging, perfusion MRI, MR
spectroscopy and perfusion CT, that require longer scan times and expertise in advanced
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imaging, which results in increased cost, examination time, and exposure to radiation.
The goal of our current study was to use texture based image analysis on routine MR
images to provide quantitative information that can be used to differentiate between
GBM and MET.

1.5.3

Objective 3: Texture analysis in patient selection for radiation
therapy

Whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) is frequently used
to treat metastatic brain tumors. However, SRS has side effects related to necrosis and
edema, and requires separate and relatively invasive localization procedures. Helical
tomotherapy (HT) allows for a SRS-type simultaneous infield boost (SIB) of multiple
brain metastases, synchronously with WBRT and without separate stereotactic
procedures. However, some patients’ tumors may not respond to HT type WBRT+SIB,
and would be more appropriately treated with radiosurgery or conventional surgery
despite the additional risks and side effects. The goal of the current study was to
investigate whether quantitative measurements of tumor size and appearance (including
first- and second-order texture features) on a magnetic resonance imaging (MRI) scan
acquired prior to treatment could be used to differentiate responder and non-responder
lesions after HT type WBRT+SIB treatment of metastatic disease of the brain.
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2

Analysis of morphological MRI parameters and diffusion
tensor parameters for perfusion CT derived high
permeability areas in glioblastoma: identifying tumor
recurrence from radiation induced necrosis
2.1

Introduction

Glioblastoma multiforme (GBM) is the most lethal and aggressive form of primary brain
tumor. Median survival for patients with glioblastoma is 12-15 months1. Treatment
options are determined by tumor size, location, and associated symptoms. Advances in
brain tumor treatment have led to aggressive management strategies utilizing
combinations of surgery, chemotherapy, and radiation therapy. The current standard of
care for patients with GBM is surgical resection of the tumor followed by radiation
therapy and concomitant and adjuvant temozolomide chemotherapy. This approach has
been shown to standardize the treatment protocol and prolong the overall survival for
patients2. Radiation Injury (RI) is an undesirable but unavoidable side effect of treatment
that appears as enhancing lesions following contrast agent injection on magnetic
resonance imaging (MRI). Since GBM is a high grade tumor, recurrences are common
after treatment, and these recurrences also manifest as hyperintense regions on MRI after
contrast agent injection. Therefore the presence of enhancing lesions after radiation
therapy may represent either tumor recurrence or radiation induced injury3, 4. Similarly,
both recurrent tumor and radiation are also known to produce hyperintense regions on
T2-weighted (T2w) and fluid attenuated inversion recovery (FLAIR) MRI. Although
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important for treatment planning and prognosis, differentiating between tumor
recurrence and RI can be difficult with conventional MRI5.
Currently tumor biopsy or histology is the gold standard for differentiating tumor from
RI. There have been various attempts to differentiate tumor recurrences from RI in the
past using in-vivo morphologic imaging as well as various functional imaging techniques
such as CT perfusion, MR perfusion, diffusion weighted imaging, magnetic resonance
spectroscopy (MRS), single-photon emission computed tomography, and positron
emission tomography5, 6-18. However, each modality has its limitations and therefore the
search for an accurate and easy to implement technique continues19.
Numerous studies have successfully correlated CT perfusion properties of the tumor with
histology and shown that progressive or recurrent tumors have high permeability (PS)
compared to RI regions20-22. CT has been widely used to obtain perfusion information in
brain tumor, but it has several disadvantages that include additional cost, examination
time, and increased exposure to radiation. Since MRI is part of routine brain tumor
imaging, an MRI technique that provides similar information would be advantageous.
The purpose of the current study was to determine whether a multiparametric
characterization of tissue based on T2w signal intensity, FLAIR signal intensity, and
diffusion tensor imaging parameters could differentiate RI from tumor recurrence.
Tumor recurrence was defined as tissue with high permeability and high blood volume
measured by CT perfusion. RI was defined as tissue with low permeability measured by
CT perfusion that was hyperintense on FLAIR MRI23-24.
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We hypothesized that

correlations between MRI parameters could identify regions of high vascular
permeability and therefore could differentiate RI from tumor recurrence.

2.2

Methods

This study was approved by the University of Western Ontario Health Sciences Research
Ethics Board. All patients provided written informed consent prior to imaging. Twelve
patients with glioblastoma multiforme were recruited for the study. Patients were eligible
for this study if they met the following criteria: histologically proven cancer before
radiation and chemotherapy, magnetic resonance imaging findings on follow-up clinical
MRI and clinical presentation consistent with glioblastoma. Patients underwent a
perfusion CT scan and a 3 Tesla MRI. Of the twelve patients, two did not complete the
perfusion CT scan and two patients showed no increase in permeability values and
therefore could not be used in the analysis. Higher permeability values were
approximately ten times the normal values. Table 2.1 shows the patient demographics
and tumor location.
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Table 2.1 Patient demographics and clinical information.
Patient

Gender, Age

Brain tumor location

1

M, 44

Lt. Parietal

2

M, 46

Lt. Parietal, Corpus Callosum

3

M, 57

Lt. Parieto-Occipital

4

M, 50

Lt. Temporal

5

F, 64

Rt. Parietal

6

M, 56

Lt. Temporal

7

F, 63

Rt. Temporal-Occipital

8

M, 43

Rt. Frontal

MR imaging was performed on a 3T Tim Trio MRI system (Siemens Medical Systems,
Erlangen, Germany) with a 32-channel head coil. The MR imaging protocol included the
following sequences: transverse T2-weighted (T2w) fast spin-echo (repetition time= 6000
ms, echo time = 93 ms, field of view = 220 mm, slice thickness = 2 mm; matrix = 320 ×
320), transverse FLAIR (repetition time = 9000 ms, inversion time = 2500 ms, echo time
= 91 ms, field of view = 256 mm, slice thickness = 5 mm; matrix = 256 x 256), and
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diffusion-weighted spin-echo imaging (repetition time = 7500 ms, echo time = 90 ms,
number of directions = 64, field of view = 256 mm, b-value = 1000, slice thickness = 2
mm; matrix = 128x128).

2.2.1

CT Perfusion Imaging

The patients were scanned on a GE CT scanner (GE LightSpeed VCT; GE Healthcare,
Waukesha, WI) with a nonionic contrast bolus (Iomeron, 350 mg iodine/mL, 40 mL;
Bracco Imaging Scandinavia, Goteborg, Sweden). A two-phase CT perfusion scan,
guided by a prior non-contrast CT scan that identified eight 5 mm sections to cover the
tumor, was performed for each patient. The bolus of contrast was injected into the vein at
a rate of 2 to 4 mL/s at 3 to 5 seconds after the first phase started. The preselected brain
sections were scanned for 45 seconds at 1-second intervals during the first phase and for
a period of 105 seconds at 15-second intervals during the second phase. All patients were
scanned at 80 kVp with a 250 mm field of view.

2.2.2

Data Analysis

The CT perfusion studies were analyzed using the prototype version of CT Perfusion 4D
software (GE Healthcare, Waukesha, WI), which is based on the Johnson-Wilson model25
and is insensitive to the delay between arterial and tissue time-attenuation curve (TAC) to
generate a map of permeability. For each patient, the arterial and venous regions of
interest (ROIs) were automatically chosen by the software in one of the anterior cerebral
arteries and the posterior superior sagittal sinus, respectively. The venous TAC was used
as a reference to correct for the partial volume averaging of the arterial TAC25. Tissue
TACs were measured from 2 x 2 pixel blocks of the CT images. Parametric perfusion
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maps of permeability (PS) were calculated by deconvolving the arterial TAC with each
tissue TAC using the Johnson-Wilson model25.
The diffusion tensor imaging (DTI) data were analyzed using Brainvoyager QX software
(Brain Innovation, Maastricht, The Netherlands). From the DTI dataset six independent
elements of the diffusion tensor were determined for each voxel, and the eigen values
(λ1, λ2, λ3) of the diffusion tensor were calculated. The eigen value information was used
to calculate the following diffusion tensor parameters26: mean diffusivity (MD),
fractional anisotropy (FA), axial diffusivity (AxD) and radial diffusivity (RD) as shown
in the following equations (1-4):
𝑀𝐷 = 𝜆1 + 𝜆2 + 𝜆3

[2.1]

���2 +(𝜆2−𝜆)
���2 + (𝜆3−𝜆)
���2

3
(𝜆1−𝜆)
𝐹𝐴 = � �

𝜆12 + 𝜆22 + 𝜆32

2

[2.2]

𝐴𝑥𝐷 = 𝜆1

[2.3]

𝑅𝐷 =

[2.4]

(𝜆2+ 𝜆3)
2

The diffusion tensor maps of MD, FA, AxD, RD, the T2w images, the FLAIR images,
and the permeability maps were all coregistered in 3D slicer27.
Three regions of interest (ROIs) were selected for each patient. The ROIs were selected
using the PS map and the coregistered FLAIR images simultaneously. ROI1 was defined
within a high permeability region on the PS map and a high signal intensity region on
FLAIR. ROI1 was labeled as a high permeability region attributed to tumor. ROI2 was
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defined as a high signal intensity region on FLAIR with normal permeability on the PS
map and attributed to radiation induced necrosis (RI). A region on the white matter on
the contralateral side with normal signal intensity on FLAIR and normal permeability on
the PS map was selected as ROI3, and labeled as normal tissue. For each patient, the
three ROIs were used to extract the mean MD, FA, AxD, and RD values from the
diffusion tensor maps and the mean T2-weighted and FLAIR signal intensities. The
values in ROI1 (high permeability) and ROI2 (RI) were normalized by the values in the
normal tissue on the contralateral side. These normalized values were used for statistical
comparisons.
All statistical comparisons were performed with SPSS software version 21 (SPSS, IBM,
Chicago, IL). Independent sample t-tests were conducted to determine if there were
differences in the normalized DTI parameters, the T2w signal intensity (SI) and FLAIR
signal intensity between the high permeability region and RI region. A Pearson productmoment correlation was computed to determine whether there was an association
between the measured MRI parameters in both the high permeability (tumor) and low
permeability (RI) regions.

2.3

Results

A typical FLAIR image (Figure 2.1A), T2W image (Figure 2.1B), CT perfusion map
(Figure 2.1C), and blood flow map (Figure 2.11D) from a single subject were used to
visualize the tumor and tissue with RI. The FLAIR image with the corresponding
permeability map overlaid is shown in Figure 2.1E. Based on these images, regions of
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interest in the high permeability area (green), the high intensity area (brown), and the
normal area (yellow) on the contralateral side were defined (Figure 2.1F).

Figure 2.1a-f FLAIR, T2w images, PS and CBV maps, and the ROIs used for
analysis.
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Table 2.2 provides the mean and standard deviation (SD) of each measured parameter in
the high permeability (tumor) and low permeability (RI) regions and the p-values. There
were no significant differences in the T2w (p =.94) and FLAIR (p = .99) signal intensities
between the high permeability region and the RI region. Also there were no significant
differences in the diffusion tensor parameters FA (p = .82), MD (p = .44), AxD (p = .33)
and RD (p = .56) comparing the high permeability region to the RI region.
Table 2.2 Parameters measured in the high permeability and RI regions.
Normalized
Parameters

High Permeability Region

RI Region

p-value

(mean ± SD)

(mean ± SD)

FA

.73 ± .29

.77 ± .35

.82

MD

1.14 ± .47

.97 ± .36

.44

AxD

1.04 ± .42

.87 ± .24

.33

RD

1.23 ± .54

1.07 ± .50

.56

T2w SI

.96 ± .33

.94 ± .42

.94

FLAIR SI

.94 ± .43

.94 ± .36

.99

As expected, there was a strong positive correlation between MD and RD (r = .98, p <
.01) in both the high permeability (tumor) region and in the low permeability (RI) region
(r = .98, p < .01). The low permeability (RI) region also produced a strong negative
correlation between FA and RD (r = - .76, p < .05) and a strong positive correlation
between T2w signal intensity and FLAIR signal intensity (r = .89, p < .01). These
associations are summarized in Figure 2.2.
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Figure 2.2a-f Scatterplots summarizing the correlation analysis.
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2.4

Discussion

Differentiating radiation injury (RI) from recurrent or progressive tumor in patients with
glioblastoma is essential since the prognoses and treatment for the two entities is
different. Conventional morphologic imaging alone has failed to differentiate tumor
regions from RI regions. With the advent of newer aggressive treatment options, RI is on
the rise and the follow-up imaging of patients over time is becoming more complex.
Diffusion MRI has shown promise in differentiating these two entities to a limited
extent5,

13

. Various other imaging techniques also offer moderate success due to the

complexity of the tissue microenvironment and the inherent limitations of these
modalities and techniques.
The goal of this study was to determine whether morphological MRI and diffusion tensor
imaging (DTI) could differentiate tumor recurrence from RI. The morphological
parameters we explored were T2w SI and FLAIR SI, while the diffusion tensor
parameters we explored were FA, MD, AxD, and RD. We did not find any statistically
significant differences in the means of the measured parameters in the high permeability
(tumor) region and the low permeability (RI) region.
There was a significant correlation between MD and RD in both the high permeability
region and RI region. Such a correlation is expected because infiltrating tumor cells can
cause an increase in MD and RD while edema from radiation damage can also cause a
similar increase31. Therefore the correlation between MD and RD may not be a good
marker to distinguish the two regions. Interestingly, a significant negative correlation was
observed between FA and RD and a significant positive correlation was observed
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between T2w SI and FLAIR SI in the low permeability (RI) region. A decrease in FA
can be caused by vasogenic edema due to radiation injury13, 29, which can in turn cause an
increase in RD (the radial component of diffusion)30. Therefore the presence of vasogenic
edema could explain why FA has a significant negative correlation with RD in the RI
region. These correlations were not observed in the high permeability (tumor) region.
Therefore, the correlations between FA and RD, and between T2w SI and FLAIR SI may
differentiate these two regions.
Further work is needed to determine whether these correlations could help differentiate
high permeability regions from radiation injury. One possible approach would involve
identifying suspicious regions and then correlating DTI parameter values and
mophological MRI values on a pixel-by-pixel basis from within the ROI. If a significant
correlation was found, it may indicate radiation injury. This success of this approach
depends on the heterogeneity of the tissue within the ROI.
To date, no objective study on correlation analyses of diffusion tensor parameters has
shown any diagnostic potential in patients with glioblastoma multiforme. Our study had
several limitations. First, the patient population was small, and further investigation with
a larger patient population is necessary to confirm these preliminary findings. Further
large-scale studies would provide estimates of the accuracy and diagnostic utility of this
new method. The second limitation of this study is the use of permeability maps to select
possible tumor regions. There have been numerous studies that have successfully
correlated perfusion properties of tumors with histology, and shown that progressive or
recurred tumors have high permeability compared to RI regions20-22. Ideally in a future
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study the tumor regions would be confirmed histologically, which is the current gold
standard.
Perfusion CT is widely used for differentiating RI from tumor tissue but has several
disadvantages that include additional cost, examination time, increased exposure to
radiation, and increased post-processing and reading time. Obtaining similar information
directly from MRI would circumvent these disadvantages. T2, FLAIR and DTI are part
of routine clinical MRI protocols for brain tumor patients. The results of the present study
suggest that correlations observed among routine MRI parameters may help differentiate
RI from tumor.
In conclusion, our results indicate that the significant correlations of diffusion tensor
imaging parameters FA and RD, along with the significant correlations of morphological
MRI parameters of T2w SI and FLAIR SI, could be used to differentiate recurred tumor
from RI regions in patients with GBM.
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3

Differentiating between glioblastoma and metastasis
using first- and second-order MR image texture
3.1

Introduction

Glioblastoma multiforme (GBM) and metastasis (MET) are the two most common types
of brain tumors in adults1. These tumors can have similar appearance on magnetic
resonance imaging (MRI) specifically a necrotic mass surrounded by ring-like
enhancement and extensive edema2-4. Discriminating between these two types of tumor
remains challenging when the patient presents with a solitary enhancing mass, since both
types of tumors exhibit similar radiologic appearance4. Differentiating between GBM and
MET is very important because they have different biological mechanisms and require
different treatment strategies5, 6. Histopathologic analysis of a biopsy sample from the
tumor region is the only currently accepted method to make a definitive diagnosis7, 8. The
use of noninvasive methods is preferable and sometimes mandatory when a biopsy is not
possible because of the general condition of the patient or if the mass is located near a
critical area. Therefore, it would be clinically beneficial to have a noninvasive method of
differentiating between these tumor types without the need for biopsy9. Since routine
MRI is not very useful for non-invasively differentiating between these two types of
tumor, many studies have focused on advanced imaging modalities, such as diffusion
tensor imaging10-13, perfusion MRI14,15, MR spectroscopy16-19 and perfusion CT20-23. The
advanced imaging modalities that have been used require longer scan times, expertise in
advanced imaging, and additional imaging modality like CT which increases cost,
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examination time, and patient exposure to radiation. Since MRI is part of the routine
brain tumor imaging, a technique based on routine MRI that would provide quantitative
information without the additional cost would be highly advantageous.
Image texture analysis has been used in a range of studies for classifying tissues24-26 in
breast and brain tumors. Image texture is a function of the spatial variation of pixel
intensities in an image27. Texture analysis can provide quantitative information that is
not visible to human vision28. The most common technique to compute image texture is
to use statistical based methods, namely first- and second-order textures, which analyze
properties of individual pixel intensities and their spatial distribution within the image.
The purpose of the current study was to determine whether first- and second- order image
texture properties of GBM and MET could be used to differentiate between these two
types of tumor. We hypothesized that the texture properties of GBM and MET tumor
tissue on post-contrast T1-weighted (T1w) MRI are different, and therefore these texture
properties could be used to differentiate GBM from MET. This study compares four firstorder texture features: the mean signal intensity, standard deviation of the signal
intensity, skewness, and kurtosis; and five second-order texture features: entropy,
homogeneity, inertia, correlation, and energy of GBM and MET tumors.
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3.2

Methods

Thirty-Nine (39) patients with a diagnosis of brain metastasis and 31 patients with a
diagnosis of glioblastoma multiforme were evaluated retrospectively for this study. All
patients had undergone routine brain MR examination before radiation treatment and/or
surgical resection at London Health Sciences Center, Canada. The tumors that were
resected fulfilled the 2007 WHO histopathologic criteria for diagnosis1.
MR imaging was performed on a 1.5T GE Signa MRI system (GE Healthcare,
Milwaukee, Wisconsin). The MR imaging protocol included pre- and post-contrast T1w
sequences. Post-contrast images were acquired immediately after contrast injection. A 3D
spoiled gradient echo sequence was used to acquire the T1w images with the following
parameters: repetition time: 8.84 msec, echo time: 3.47 msec, slice thickness: 2 mm,
matrix size: 512 × 512, flip angle: 13º.
3D lesion contouring on the post-contrast T1w MR images was performed under the
supervision of a radiation oncologist with expertise in the treatment of brain tumors using
ITK-SNAP (Version 2.4.0)29. The contours were saved as 3D label maps. Figure 3.1
shows the post-contrast T1w images of GBM and MET lesions, with the contours
overlaid on the images.
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Figure 3.1 Post-contrast T1w image of GBM and MET lesion, with the contour
overlaid.
Type of tumor

Post-contrast
image

T1w Contour overlaid

GBM

MET

3.2.1

Data Analysis

All calculations were performed using Matlab 7.1. (The Mathworks Inc., Natick, MA,
USA). For each lesion, we calculated the following first- and second-order texture
features: (1) mean T1w signal intensity, (2) standard deviation of the T1w signal
intensity, (3) skewness, (4) kurtosis, (5) information entropy of the T1w signal intensity
histogram, (6) homogeneity, (7) inertia, (8) energy, and (9) correlation. Features (1)
through (4) are first-order texture measures that are estimated from individual pixel
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values in the tumor region. Features (5) through (9) are second-order texture features
that were calculated based on a gray-level co-occurrence matrix (GLCM)30, 31, 32.
The GLCM approach is based on the use of second-order statistics of the grayscale image
histograms and is an estimate of the second-order joint probability G(i, j) of the intensity
values of two pixels (i and j), at a certain pixel distance apart along a given direction (i.e.,
the probability that i and j have the same intensity). This joint probability takes the form
of a square matrix with row and column dimensions equal to the number of discrete gray
levels (intensities) in the image. If an intensity image contained no texture the resulting
GLCM would be completely diagonal. As the image texture increases (i.e. as the local
pixel intensity variations increase), the off-diagonal values in the GLCM become larger.
The images were quantized to thirty-two gray levels, and four 32 × 32 GLCMs were
computed with neighboring pixels defined in angular directions of 0, 45, 90 and 135. The
resulting texture features were averaged over the four directions. Each GLCM-based
second-order texture feature was calculated as follows:
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Table 3.1 GLCM-based second-order texture features
Feature

Equation

Entropy

Measures the randomness of the GLCM.

− � 𝐺(𝑖, 𝑗) 𝑙𝑜𝑔2 𝐺(𝑖, 𝑗)

Homogeneity

𝑖,𝑗

�
𝑖,𝑗

Inertia

Correlation

�
𝑖,𝑗

Energy

Description

1
𝐺(𝑖, 𝑗)
1 + |𝑖 − 𝑗|

Measures the closeness of the distribution
of elements in the GLCM to the GLCM
diagonal.

�(𝑖 − 𝑗)2 𝐺(𝑖, 𝑗)
𝑖,𝑗

Measures the intensity contrast between a
pixel and its neighbor over the whole
image. Describes the local variations in the
GLCM.

(𝑖 − 𝜇)(𝑗 − 𝜇)𝐺(𝑖, 𝑗)
𝜎2

Measures how correlated a pixel is to its
neighbor over the whole image. Describes
the joint probability occurrence of the
specified pixel pairs.
Measures sum of the squared elements of
the GLCM. It describes the uniformity of
the image.

� 𝐺(𝑖, 𝑗)2
𝑖,𝑗

3.2.2

Statistical Analysis

All statistical analysis was performed using SPSS software (IBM SPSS, Version 21,
Chicago, IL). Kolmogorov-Smirnov test was used to assess the normality of the data.
Mann-Whitney U test was conducted to test the differences between the two groups
(GBM and MET). P < .05 was considered to indicate a statistically significant difference.
The efficacy of the texture features for classification was evaluated using logistic
regression analysis. The first- and second-order texture features were combined into a
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multivariate logistic regression analysis to determine the most significant parameters
and to build an optimal logistic regression model (LRM) to classify GBM and MET.
Model fit was evaluated by means of the Hosmer–Lemeshow goodness-of fit test33.
Areas under the receiver operating characteristic (ROC) curves were computed for each
of the first- and second-order texture features. ROC curves were also computed for the
predictive features that were the calculated from the LRM. ROC curve analyses were
performed to determine optimum threshold and the diagnostic accuracy of each
histogram parameter for discriminating the two types of tumors. These analyses allowed
us to determine the sensitivity, specificity, 95 % confidence interval (CI), standard error
(SE), and area under the curve (AUC) associated with each individual texture parameter
and combined texture parameter as a function of the threshold value used to discriminate
the two types of tumors.
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3.3

Results

The independent samples Mann-Whitney U test for the first-order texture features
showed significant differences in the standard deviation of the T1w signal intensity for
the GBM and MET groups. No differences were found in T1w signal intensity, skewness
and kurtosis between the GBM and MET groups. Table 3.2 shows the mean and standard
deviation (SD) of each first-order texture feature for the GBM and MET, as well as the
result of the Mann-Whitney U test for each feature. Figure 3.2 summarizes the results in
form of bar graphs for each of the first-order texture feature.

Table 3.2 Mean and SD of each of the first-order texture feature.
First-Order Texture

GBM

MET

Feature

(mean ± SD)

(mean ± SD)

1382 ± 660.62

1194 ± 808.27

.08

438 ± 258.21

312 ± 235.29

.02

.159 ± .39

.079 ± .50

.52

2.85 ± .74

2.97 ± .63

.22

T1w Signal Intensity
SD T1w Signal Intensity
Skewness
Kurtosis
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p-value

The independent samples Mann-Whitney U test for the second-order texture features
showed significant differences in the entropy, homogeneity, inertia and energy feature for
the GBM and MET groups. No differences were found in the correlation feature for the
GBM and MET groups. Table 3.3 shows the mean and standard deviation of each
second-order texture feature for the GBM and MET, as well as the result of the MannWhitney U test for each feature. Figure 3.3 summarizes the results in form of bar graphs
for each of the second-order texture feature.

Table 3.3 Mean and SD of each of the second-order texture feature.
Second-Order Texture GBM

MET

p-value

Feature

(mean ± SD)

(mean ± SD)

Entropy

10.18 ± 1.11

9.32 ± 1.46

.007

Homogeneity

.995 ± .003

.998 ± .001

.000

Inertia

.320 ± .183

.155 ± .092

.000

Correlation

.915 ± .047

.914 ± .065

.615

Energy

.981 ± .013

.992 ± .005

.000
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Figure 3.2 Plots of the first-order texture features for GBM and MET. Standard
deviation of the T1w signal intensity was the only significantly different feature
between the two tumor types.
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Figure 3.3 Plots of the second-order texture features for GBM and MET. Contrast,
homogeneity, energy and entropy features were significantly different between the
tumor types.
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3.3.1

ROC curve analysis:

Each texture feature was evaluated for its discriminative ability using ROC analysis as
shown in Table 3.4 and Figure 3.4, 3.5 and 3.6. When used alone, second-order texture
feature of inertia (AUC= .790) was the best feature for discrimination, followed by
homogeneity (AUC= .776), energy (AUC= .752) and entropy (AUC= .688). The firstorder texture features of mean of the T1w signal intensity (AUC= .621), standard
deviation of the T1w signal intensity (AUC= .659), skewness (AUC= .544) and kurtosis
(AUC= .585) were not very useful in discriminating the tumor types.
The LRM of the combined first- and second-order texture features was the most accurate
in differentiating the tumor types with AUC= 0.885, sensitivity = 90.3%, specificity =
82.1 % and cutoff value = 0.673. The LRM of the second-order texture features also
showed good accuracy differentiating the tumor types with AUC= 0.840, sensitivity =
83.9 %, specificity = 66.7 % and cutoff value = 0.708 compared to the individual secondorder textures. The LRM of the first-order texture features was a poor discriminator of
the tumor types with AUC= 0.658, sensitivity = 61.3%, specificity = 64.1 % and cutoff
value = 0.562. The optimum threshold, sensitivity, and specificity of each texture
parameter and combined texture parameters to distinguish the two tumor types are
summarized in Table 3.4
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Table 3.4 ROC curve analysis for each of the first- and second-order texture
features and combination of the first- and second-order texture features for
differentiation between GBM and MET. (the cut-off value was chosen as a point on
the ROC curve that maximizes sensitivity + specificity)
Texture Feature

Cut-off Value

Sensitivity Specificity

AUC SE

CI

1073

61.3

56.4

.621

.067

(.49, .75)

305

67.7

64.1

.659

.065

(.53, .78)

.054

58.1

48.7

.544

.069

(.40, .68)

2.91

64.5

56.4

.585

.070

(.44, .72)

9.74

71.0

64.1

.688

.064

(.56, .81)

.998

74.2

71.8

.776

.062

(.65, .89)

.180

71.0

71.8

.790

.054

(.68,.89)

.929

64.5

53.8

.535

.072

(.39, .67)

.992

74.2

66.7

.752

.063

(.62, .87)

.562

61.3

64.1

.658

.067

(.52, .79)

.708

83.9

66.7

.840

.047

(.74, .93)

.673

90.3

82.1

.885

.043

(.80, .97)

Mean T1w
Std T1w
Skewness
Kurtosis
Entropy
Homogeneity
Inertia
Correlation
Energy
First order
Second order
First + Second
order
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Figure 3.4 ROC curves for each of the first-order texture measures: mean T1w
signal intensity (AUC= .621), standard deviation (std) of the T1w signal intensity
(AUC= .659), skewness (AUC= .544) and kurtosis (AUC= .585). All four features
have poor predictive value.
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Figure 3.5 ROC curves for the second-order texture measures: entropy (AUC =
.688), inertia (AUC= .790), homogeneity (AUC= .776), correlation (AUC= .535), and
energy (AUC= .752). Inertia, homogeneity and energy (next page) are the best
predictors for differentiating between GBM and MET when used alone.

89

Figure 3.5 (contd): ROC curve for the second-order texture measure of energy.

Figure 3.6 ROC curves for the first order textures (AUC = .658), second-order
textures (AUC = .840) and combined first + second-order texture measures (AUC =
.885). Combining the first and second order textures may provide the best predictive
accuracy for differentiating between GBM and MET.
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3.4

Discussion

GBM and MET typically demonstrate similar appearances on routine MR imaging. Since
they have same clinical symptoms but different treatment strategies, a technique is
needed to differentiate between these two types of tumors. In this study we investigated
the feasibility of using texture-based analysis of routine MR images to differentiate GBM
from MET. Texture analysis provides quantitative information about the spatial variation
of pixel intensities in an image.
We investigated four first-order texture features (mean T1w signal intensity, standard
deviation of the T1w signal intensity, skewness, and kurtosis) and five second-order
texture features (entropy, homogeneity, inertia, correlation, and energy). First-order
texture features are computed from gray level histogram while second order texture
features are computed from the gray level co-occurrence matrix (GLCM) which analyzes
gray level distribution of pairs of pixels. Figure 3.8a and 3.8b show sample GBM and
MET images having similar radiologic appearance, where the second-order texture
features of inertia, energy, and homogeneity are able to successfully differentiate between
GBM and MET.
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GBM

MET

Inertia

7.475

5.594

Energy

0.0050

0.0133

Homogeneity

0.4468

0.5336

b

GBM

MET

Inertia

9.248

3.114

Energy

0.0136

0.0186

Homogeneity

0.4987

0.6063

a
Image

Image

Figure 3.4a,b GBM and MET tumors showing similar appearance on routine MR
image but differences in the second-order texture measures.

A statistically significant difference was observed in the standard deviation of the mean
T1w signal intensity. The first-order texture features of mean, skewness, and kurtosis did
not show any significant differences between the two types of tumors. A statistically
significant difference was observed in the second-order texture features of entropy,
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inertia, homogeneity, and energy. No statistically significant difference was seen in the
second-order texture feature of correlation.
ROC analysis showed that the combination of first- and second-order texture features had
the largest AUC (0.88) and would have the best predictive accuracy for differential
diagnosis between GBM and MET, followed by the combined second-order texture
features (AUC= 0.84). The individual second-order texture features of inertia (AUC=
.79), homogeneity (AUC= .77), and energy (AUC= .75) also showed good predictive
accuracy. The combined first-order texture features (AUC= .65) was not very useful in
differentiating the tumor types.
Other investigators have used advanced imaging techniques including diffusion and
perfusion to differentiate between the two types of tumor10-15. Previous studies have also
used a region of interest (ROI) approach within the whole tumor to derive imaging
parameters for differentiation. However, this may not be the suitable approach since a
small ROI in a large tumor may not provide information about the changes occurring
within the tumor and may not be a good indicator of the global change within the entire
tumor. Our technique is unique in several ways: (1) This is the first study to apply firstand second-order texture analysis for differentiating between GBM and MET tumors, (2)
we use the routine clinical MR images instead of advanced imaging modalities to
discriminate between the two tumor types, which saves time and cost; (3) we use a
whole-tumor approach rather than small ROIs drawn inside the tumors. Our approach
yields information about the textural properties of the whole tumor rather than a small
ROI within the tumor: and (4) the simplicity of implementation makes it desirable than
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other techniques. Simple mathematical calculations are used to compute the texture
parameters.
A limitation of this study is the small sample size. Features that may have less effect on
the differentiation may have been missed. Features which were approaching significance,
such as the mean of the T1w signal intensity (p =.08), may become statistically
significant with a larger sample size. Even within our sample size we had significant
effects that were useful, suggesting that the texture features we found to be significant are
important in differentiating GBM from MET. Another limitation is that the performance
of the LRM is unclear without the use of a separate validation set, and further evaluation
of the models need to be explored in future work on a larger data set.

3.5

Conclusions

We have demonstrated the ability of texture-based analysis of routine MR images to
differentiate between GBM and MET. Our results indicate that the combination of firstand second-order texture features provides us with the highest predictive accuracy
followed by the combined second-order features. When used individually, the second
order texture feature of inertia had the best predictive accuracy followed by homogeneity
and energy. Given the simplicity of our technique and availability of the post-contrast
T1w MR images which are part of the routine brain tumor imaging, we believe this
method may have practical significance and may become a useful tool for differentiating
between GBM and MET.
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4

MRI-based prediction of response to whole-brain helical
tomotherapy with simultaneous intralesional boost for
metastatic brain cancer using quantitative size and
appearance features
4.1

Introduction

Metastatic brain tumors are an important public health issue, with 20%–40% of patients
having solid tumors subsequently developing symptomatic brain metastases1, and
approximately 150,000 annual brain metastasis diagnoses annually in the United States.
With recent improvements in diagnostic imaging and increasing patient survival due to
improved systemic cancer control, the incidence of intracranial metastatic disease is
projected to rise2. Whole brain radiotherapy (WBRT) is widely used in the treatment of
patients with metastatic disease and involves the delivery of a uniform dose of radiation
to the entire brain3. It improves symptoms, but longer-term survivors may develop
neurocognitive deficits4, 5. Stereotactic radiosurgery (SRS) is a more targeted form of
radiation therapy in which a higher dose of radiation is delivered to the tumor in a single
treatment session. SRS combined with WBRT has been shown to yield superior local
control, as compared with WBRT alone6. However, SRS has a higher frequency of side
effects related to brain tissue necrosis and edema, which can put pressure on surrounding
healthy brain tissue. SRS also requires separate localization and treatment procedures that
add cost and patient inconvenience. Depending on the SRS system used, invasive
immobilization devices may be needed, increasing patient discomfort. In addition, the
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sequential delivery of WBRT and SRS does not allow integration of radiation delivery
across both components, limiting the ability to fully optimize the radiation dose.
Helical tomotherapy (HT) and volumetric modulated arc therapy (VMAT) are two
radiotherapy delivery technologies that allow for radiosurgery-type simultaneous infield
boost (SIB) treatments to be given synchronously with the standard WBRT dose, and in
this way be used to efficiently boost multiple brain metastases without the need for
separate stereotactic procedures7,8. The ability to incorporate this boost contribution with
larger field volumes as part of the treatment planning optimization process provides an
advantage of this WBRT+SIB strategy over sequential WBRT and SRS. During
fractionated radiotherapy, reassortment and reoxygenation may occur between
treatments, resulting in increased efficacy of subsequent doses in the treatment course;
single-fraction treatments cannot exploit these radiobiologic properties9. Although
WBRT+SIB has potential advantages compared to surgery and SRS, it is not necessarily
appropriate for every patient. Some patients’ tumors may not respond to WBRT+SIB,
and would be more appropriately treated with radiosurgery or conventional surgery
despite the additional risks and side effects. A means for predicting response to
WBRT+SIB based on pre-treatment imaging could support the selection of the best
treatment for each individual lesion as early as possible while the metastatic lesion has
the greatest chance of control.
As a first step toward a broader objective of developing a means for response prediction
to WBRT+SIB, the goal of this study was to determine whether quantitative
measurements of tumor size and appearance on a magnetic resonance imaging (MRI)
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scan acquired prior to treatment could be used to differentiate responder and nonresponder lesion groups after WBRT+SIB using HT (henceforth WBHT+SIB) treatment
of metastatic disease of the brain. In this study, we used the longest axial diameter (as
used in Response Assessment Criteria in Solid Tumors [RECIST] measurements10 and
the 3D volume as the measure of tumor size. To measure imaging appearance, we used
three first-order features (the mean signal intensity, standard deviation of the signal
intensity, and skewness of the intensity histogram) and five second order texture features
(entropy, homogeneity, inertia, correlation and energy).

4.2
4.2.1

Materials and methods
Materials

This study was approved by the Human Subjects Research Ethics Board of our institution
and informed consent was obtained from all patients. We recruited 21 patients for the
study. These 21 patients had a total of 31 lesions. Inclusion criteria were: histologic
diagnosis of primary cancer; contrast-enhanced MRI demonstrating 1–3 metastases
within 6 weeks of study enrollment; age≥ 18 years; Karnofsky performance status ≥ 70;
anticipated survival ≥ 3 months; extracranial disease controlled; to be treated, or absent.
Exclusion criteria were: metastases not suitable for SIB (> 3 lesions or any lesion
maximum diameter > 3 cm, metastases within 5 mm of brainstem or optic apparatus,
evidence of leptomeningeal spread, intracranial extension of an osseous metastasis,
evidence of intraventricular or subependymal growth), prior cranial radiotherapy,
concurrent cytotoxic chemotherapy, contraindications to MRI or gadolinium contrast.
The patients underwent HT with 30 Gy WBRT and 60 Gy SIB in 10 fractions at the
101

London Regional Cancer Program, London Health Science Centres, Canada. Figure 4.1
illustrates the isodose curves for a 60 Gy/10-fraction WBHT+SIB case.

Figure 4.1 Isodose curves for an HT plan, illustrating a whole brain radiation plan
(yellow = 30Gy) with integrated high-dose boost (purple = 60Gy) to a metastatic
lesion.

For each patient, we acquired pre-treatment and post-treatment T1-weighted (T1W)
gadolinium contrast-enhanced MRI scans (for an overall total of 21 × 2 = 42 scans) using
3D spoiled gradient echo sequence (repetition time: 8.84 msec, echo time: 3.47 msec,
slice thickness: 2 mm, matrix size: 512 × 512, flip angle: 13º). The mean time between
the baseline and follow-up scans was 3.4 months (range 1–6 months). Imaging was
performed on a 1.5 Tesla General Electric Signa HDxt MRI scanner (GE Healthcare,
Waukesha, WI, USA).
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Patient 1

Patient 2

Patient 3

Pretreatment
Image

Posttreatment
image

Figure 4.2 Sample images of brain metastases at the pre-treatment and follow-up
imaging time points, with manual contours overlaid in red. Note the variability of
MRI appearance of the different lesions.

Table 4.1 Primary site of metastasis for non-responders and responders

Primary Site

Number of Nonresponding lesions

Number of
Responding lesions

Breast

4

1

Melanoma

3

3

Lung

1

8

Colon

1

0

Kidney

4

0

Parotid

1

0

Thyroid

1

0

Prostate

0

3

Unknown

1

0
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Figure 4.3 Representative axial cross sections from inferior (left) to superior (right)
of two tumors, one in each row. The tumor in the first row (a) had a standard
deviation of 375.79 within its core region. The tumor in the second row (b) had a
standard deviation of 238.97 within its core region. The higher standard deviation
value in the upper tumor is reflective of the more variegated texture within the
tumor; bright pixels are sometimes neighbouring bright pixels, but are also
sometimes neighbouring dark pixels; the correlation between intensities of
neighbouring pixels is not as high as in the tumor in the second row.
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4.2.2

Methods

3D lesion contouring on the post-contrast T1W MR images was performed by a radiation
oncologist with expertise in treatment of brain metastases using ITK-SNAP (Version
2.4.0) for all the baseline and follow-up lesions11. The regions enclosed by the contours
were recorded as 3D binary label maps. All subsequent image processing and data
analysis was performed using Matlab 7.1 (The Mathworks Inc., Natick, MA, USA).
The longest diameter lying entirely within tumor tissue on any axial slice for each lesion
was calculated based on the 3D binary label maps according to the Response Evaluation
Criteria in Solid Tumors (RECIST) 1.1 guidelines10. For each lesion, the percentage
change in RECIST was calculated as 100% × (follow-up RECIST - baseline RECIST) /
baseline RECIST. Lesions with a percentage change in RECIST of ≤ -30% were grouped
as responders (15 lesions), with the remainder of the patients grouped as non-responders
(16 lesions), according to the RECIST guidelines for clinical assessment10.
Measures of size and appearance were computed on each 3D contoured tumor, as well as
on two tumor subregions, defined as follows. The 3D binary label maps were
automatically separated by software into two regions: a peripheral region intended to
correspond to the tumor rim, and the remaining region intended to correspond to the
tumor core. The rim was defined as the set of image voxels within 3 mm of the tumor
boundary on each slice within each 3D tumor. The core was defined as the set of image
voxels on the inside of the tumor and not within the rim.
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Inspired

by

qualitative

categorizations

of

metastases

as

“homogeneous”,

“heterogeneous”, and “rim-enhancing” in related work in the SRS context12,13, we
calculated the following features for each tumor and its subregions: (1) 3D tumor volume
(number of voxels within the contoured tumor × voxel size), (2) tumor diameter, (3)
mean T1W signal intensity, (4) standard deviation of the T1W signal intensity, (5)
skewness, (6) information entropy of the T1W signal intensity histogram, (7)
homogeneity, (8) inertia, (9) energy, (10) correlation, and (11) the ratio of mean intensity
within the rim to mean intensity within the core (henceforth rim:core ratio). Features (1)
and (2) are size measures. Features (3)–(5) are first-order appearance and texture
measures. Features (6)–(10) are a subset of the Conners and Harlow second-order texture
features14 and were calculated based on a gray-level co-occurrence matrix (GLCM) 𝑔,

where 𝑔(𝑖, 𝑗) contains the number of neighbouring pixels having intensities 𝑖 and 𝑗. Each
GLCM-based feature was calculated as follows:
homogeneity = ∑𝑖,𝑗

1

1+|𝑖−𝑗|

𝑔(𝑖, 𝑗),

inertia = ∑𝑖,𝑗(𝑖 − 𝑗)2 𝑔(𝑖, 𝑗),
energy = ∑𝑖,𝑗 𝑔(𝑖, 𝑗)2 , and
correlation = ∑𝑖,𝑗

(𝑖−𝜇)(𝑗−𝜇)𝑔(𝑖,𝑗)
𝜎2

.

Images were quantized to 60 gray levels and we computed four GLCMs with neighboring
pixels defined in angular directions of 0, 45, 90 and 135. For each axial slice containing
tumor, a single GLCM was constructed from the sum of the four GLCMs taken in each
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direction. These slice-wise GLCMs were then summed to produce a final GLCM, from
which the texture features were calculated.
Kolmogorov-Smirnov tests were used to assess the normality of the distributions of the
data. Mann-Whitney U tests were conducted to test for significant differences between
the medians of the two groups (responders and non-responders), with α = 0.05. Receiver
operating characteristic (ROC) curve analyses were performed for each feature
independently and areas under the curves (AUC) were computed. ROC curve analysis
was conducted using the SPSS software package (IBM SPSS, Version 21, Chicago, IL).

4.3

Results

Table 4.2 shows the median and interquartile range (IQR) of each feature within each
group for the whole tumor, as well as the result of the Mann-Whitney U test for each
feature. Tables 4.3 and 4.4 show the same information for the core and rim regions,
respectively, although for these regions only the appearance measures, not the size
measures, were calculated as the sizes of the rim and core are directly correlated with the
size of the whole tumor. For the whole tumor and for the core region, significant
differences in median tumor diameter, 3D volume, and second-order homogeneity,
inertia, correlation, and energy were found. For the rim region, significant differences in
homogeneity, inertia and energy were found. For the whole tumor, the 3D volume
measure had a smaller p-value, compared to the tumor diameter measure.

For all

significant differences, non-responders had larger 3D volume, diameter, inertia, and
correlation values, and smaller homogeneity and energy values. Figures 4.4, 4.5 and 4.6
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shows box and whisker plots for features found to be significant, to graphically illustrate
the differences between the groups.

Table 4.5 shows the AUC values for the three top-performing individual features, as well
as the optimal thresholds (chosen as the upper left-most points on the ROC curves). In
addition, logistic regression was done to examine combined performance of the variables,
and we calculated the AUC yielded by the combination of the best-performing size
measure (tumor 3D volume) and the best-performing appearance measure (core
correlation) to investigate whether the combination of size and appearance characteristics
would yield improved per-patient prediction of response. This combination did not
outperform the measure of core correlation. The threshold shown in Table 4.5 for this
feature combination is on the response variable from the logistic regression model.
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Table 4.2 Feature values measured for each group in the whole tumor. For rows
with p < 0.05, the larger median is underlined.

Feature

Responders

Non-responders

p-value

(median ± IQR)

(median ± IQR)

3D volume (mm3)

1326 ± 2529

3879 ± 7120

0.01

Tumor diameter

17.8 ± 12.1

24.1 ± 15.0

0.03

T1W signal intensity

1369 ± 1723.7

1199 ± 885.1

0.24

SD T1W signal intensity 466.1 ± 441.6

339.7 ± 271.6

0.39

Skewness

0.04 ± 0.56

0.11 ± 0.72

0.67

Entropy

9.7 ± 2.0

10.1 ± 1.3

0.67

Homogeneity

0.998 ± 0.001

0.997 ± 0.002

0.02

Inertia

0.25 ± 0.20

0.35 ± 0.22

0.02

Correlation

0.93 ± 0.05

0.95 ± 0.02

0.03

Energy

0.995 ± 0.004

0.993 ± 0.007

0.01

Rim:core ratio

0.73 ± 0.16

0.66 ± 0.14

0.73
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Table 4.3 Feature values measured for each group in the tumor core. For rows with
p < 0.05, the larger median is underlined.

Feature

Responders

Non-responders

(median ± IQR)

(median ± IQR)

T1W signal intensity

1382.9 ± 2005.2

1240.6 ± 900.7

0.22

SD T1W signal intensity

390.7 ± 366.8

334.6 ± 290.9

0.48

Skewness

0.09 ± 0.41

0.15 ± 0.86

0.95

Entropy

9.62 ± 2.1

9.90 ± 1.6

0.46

Homogeneity

0.9987 ± 0.001

0.9981 ± 0.001

0.02

Inertia

0.34 ± 0.28

0.44 ± 0.20

0.04

Correlation

0.90 ± 0.07

0.93 ± 0.02

<0.01

Energy

0.996 ± 0.004

0.994 ± 0.007

0.01
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Table 4.4 Feature values measured for each group in the tumor rim. For rows with
p < 0.05, the larger median is underlined.

Feature

Responders

Non-responders

(median ± IQR)

(median ± IQR)

T1W signal intensity

1082.3 ± 1100.9

830.3 ± 510.8

0.19

SD T1W signal intensity

359.2 ± 304.4

230.9 ± 235.9

0.41

Skewness

0.69 ± 0.47

0.83 ± 0.65

0.29

Entropy

9.44 ± 1.41

9.73 ± 1.5

0.82

Homogeneity

0.9986 ± 0.0008

0.9984 ± 0.0008

0.03

Inertia

0.56 ± 0.27

0.74 ± 0.29

0.03

Correlation

0.79 ± 0.02

0.79 ± 0.02

0.70

Energy

0.996 ± 0.002

0.995 ± 0.002

0.03
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Figure 4.4 Boxplots for 3D volume and Diameter for the whole tumor, the core, and
rim regions, comparing responders (R) and non-responders (NR).

Figure 4.5 Boxplots for Homogeneity and Inertia for the whole tumor, the core, and
rim regions, comparing responders (R) and non-responders (NR).
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Figure 4.6 Boxplots for Correlation and energy for the whole tumor, the core, and
rim regions, comparing responders (R) and non-responders (NR).
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Figure 4.7 ROC curves for the four features that had the largest AUCs (Table 4.4).

Table 4.5 Optimal thresholds of features having the four largest AUCs.
Features
Tumor 3D Volume
Tumor Diameter
Core Correlation
Combined (core correlation +3D volume)
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AUC
.75
.72
.77
.77

Threshold
2154
16.84
0.92
0.32

4.4

Discussion

The role of brain radiotherapy has been a source of controversy since some patient
populations show limited clinical benefit15. WBRT is widely used in the treatment of
patients with metastatic disease16 since it is technically easy to deliver and it improves
symptoms in 75% of symptomatic patients with brain metastases17,18, but long-term
survivors may develop neurocognitive deficits4,5 and local control may be inadequate,
especially in patients who live longer than a few months.
The feasibility and safety of HT+SIB using 30 Gy WBRT with intralesional boost of 60
Gy has been shown by Rodrigues et al. in a phase I clinical trial7. For selected patients
with brain metastasis, aggressive treatment of the individual lesions with high dose
radiation combined with a lower dose of radiation to the remainder of the brain has
produced the best results in terms of controlling cancer in the brain and preventing new
lesions from developing22. HT allows for radiosurgery-type SIB treatments to be given
synchronously with the standard WBRT dose, and can be used efficiently to boost
multiple brain metastases without the need for separate stereotactic procedures7,8.
Bauman et al. have shown that the WBHT+SIB strategy is also relatively independent of
the number of lesions being boosted and may be a feasible strategy for treating multiple
intracranial lesions efficiently19.
In this study, we investigated size and imaging appearance features of the whole tumor,
tumor rim and tumor core for differentiation of patient groups that would benefit from the
WBHT+SIB therapy for brain metastases. This is the first study to apply quantitative size
and imaging texture measures of tumors to measure the differences on pre-treatment
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contrast-enhanced T1-weighted MRI between responders and non-responders to helical
tomotherapy with simultaneous infield boost for intracranial metastases. Our approach
adapts and extends previous work in the stereotactic radiosurgery context by using
quantitative measures that are related to previously used categorical subjective tumor
assessments. To measure imaging appearance, we used three first-order features (the
mean signal intensity, standard deviation of the signal intensity, and skewness) derived
from the gray-level histogram, where mean and standard deviation are the mean of the
gray-levels and the measure of deviation of these gray-levels in the image, while
skewness is the asymmetry of the distribution of the gray-levels. We also tested five
second order texture features (entropy, homogeneity, inertia, correlation and energy)
which are calculated from the GLCM, where GLCM provides an estimate of the joint
probability of the intensity values of neighboring pixels. The use of these predictive
markers could help to identify the lesions which would benefit from WBHT+SIB
(responders) while sparing the non- responders which would not benefit so that the latter
may be treated with other combinations of therapies. For the former group of lesions,
WBHT+SIB may represent an effective and less invasive option compared to traditional
combinations of surgery or radiosurgery combined with WBRT.
For the whole tumor, size measures of 3D volume and diameter were significantly
different between the responders and non-responders with responders having smaller size
tumors than the non-responders. One possible explanation for the limited response of
large tumors is related to the presence of hypoxic regions. Hypoxic regions are resistant
to radiation damage23. During the course of fractionated WBHT + SIB treatment, smaller
hypoxic regions may become reoxygenated and therefore may be more sensitive to
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radiation damage. Conversely, larger tumors have bigger hypoxic regions that may need
more fractionated radiation delivery (>15 fractions) than is currently used in clinical
settings.
Appearance measure of first-order features did not show any significant differences
between the groups. Second-order features of homogeneity, inertia, correlation and
energy showed significant differences between the two groups. Figure 4.3a-b shows an
example of the differences in the standard deviation (SD) and correlation values for the
two patients. The tumor in the first row (4.3a) had a SD value of 375.79 and correlation
value of 0.89 within its core region. The tumor in the second row (4.3b) had a SD value
238.97 and correlation value of 0.97 within its core region. The lower correlation value in
the upper tumor is reflective of the more variegated texture within the tumor and the
correlation between intensities of neighbouring pixels is not as high as in the tumor in the
second row.
Since the tumor appears to have a hypodense core and a hyperintense rim, we also looked
at the first and second order texture features separately for each of the two regions (the
tumor core and tumor rim) to assess whether separating the two regions would give us
better predictive capability. For the core region, we saw similar results to that of the
tumor as a whole. Core size measures of 3D volume, tumor diameter and second-order
appearance measures of homogeneity, inertia, correlation and energy were significantly
different between the responders and non-responders groups. For the rim region, the size
measure of 3D volume and second-order features of homogeneity inertia and energy were
significantly different between the two groups. To investigate the predictive value of an
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enhancing rim and/or a necrotic core, we calculated the rim-core ratio. No significant
difference was seen for the rim-core ratio between the responder and non-responder
groups. The AUC for the ROC curve (0.46) of rim-core ratio feature was very low,
suggesting that the appearance (or lack thereof) of an enhancing rim or necrotic core on
the pre-treatment image may not predict response at first follow-up.

For all three regions (tumor, core, rim), no significant differences were seen in the firstorder features of T1w signal intensity and SD between the responders and non-responders
suggesting that the T1w signal intensity and SD may not be useful as a predictive marker
for response to WBHT+SIB therapy. The failure to detect statistical significance for the
first-order texture features for the three regions may imply that the global appearance of
the tumor may be less important than the local pixel intensity relationships to prediction
of WBHT+SIB treatment response. Further testing of this observation will require greater
statistical power with a larger sample size.
There are several limitations to this study. First, all the contours were drawn by a single
observer; further study is required to measure the impact of observer contouring
variability on the size and appearance measures used in this study. Second, our sample
size necessitates that the results of this study be considered hypothesis-generating, with
more extensive validation required on a separate data set. Third, although our study tested
a subset of the Conners and Harlow second-order texture features14, this does not
constitute an exhaustive evaluation of the texture measures that have been proposed, so
firm conclusions regarding the predictive power of appearance measures in general
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cannot be drawn from the results of this study and further investigation of alternative
texture measures is required. Fourth, the texture measure of T1w signal intensity was not
normalized. Although this parameter was not significantly different between the two
groups, factors such as coil loading may have increased the variance of the measured
signal intensity. In the future a quantitative approach should be taken24 to measure the
absolute T1 of the tissue for texture analysis. Finally, the logistic regression model's
performance on a separate validation set should be explored in future work on a larger
data set.
Metastatic brain lesion size and second order appearance as measured on pre-treatment
MRI can distinguish responders from non-responders to WBHT+SIB. . The results of this
study suggest that the 3D tumor volume and the second-order correlation texture measure
within the tumor core are the best predictors, with smaller lesions (< 2.1 cm3) and those
with a relatively smaller second order core correlation value (< 0.92) having a greater rate
of response to WBHT+SIB. The results also suggest that the longest axial diameter (as
measured in RECIST) could be a useful surrogate for 3D volume, with tumors having
diameters < 1.7 cm responding more favorably to treatment. Appearance measures in
general can quantify visual changes but they did not substantially outperform measures of
size; there is high variability of appearance in both responders and non-responders to
WBHT+SIB. The amount of rim enhancement and/or core necrosis, as reflected in our
signal intensity measures did not provide useful prediction of response. Ongoing work on
a larger sample size will include further validation of our results and the development of
an approach to per-lesion prediction of response to WBHT+SIB therapy based on pretreatment MRI, supporting optimal treatment selection.
119

4.5
[1]

References

Kondziolka D, Martin JJ, Flickinger JC, Brufsky AM, Baar J, Kirkwood JM,
Lunsford LD. Long term survivors after gamma knife radiosurgery for brain
metastases. Cancer 2005; 104(12):2784–91.

[2]

Patel TR, McHugh BJ, Bi WL, Minja FJ, Knisely JP, Chiang VL. A
comprehensive review of MR imaging changes following radiosurgery to 500
brain metastases. AJNR Am J Neuroradiology 2011; 32(10):1885-92.

[3]

Sneed PK et al., Neurosurgery Clinics of North America 1996; 7:505–515.

[4]

Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases.
Oncologist 2007; 12(7):884-98.

[5]

Asai A, Matsutani M, Kohno T, Nakamura O, Tanaka H, Fujimaki T, Funada N,
Matsuda T, Nagata K, Takakura K.. Subacute brain atrophy after radiation therapy
for malignant brain tumor. Cancer 1989; 63(10):1962-74.

[6]

Sneed PK, Lamborn KR, Forstner JM, McDermott MW, Chang S, Park E, Gutin
PH, Phillips TL, Wara WM, Larson DA. Radiosurgery for brain metastases: is
whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys. 1999;
43(3):549-58.

[7]

Rodrigues G, Yartsev S, Yaremko B, Perera F, Dar AR, Hammond A, Lock M, Yu
E, Ash R, Caudrelier JM, Khuntia D, Bailey L, Bauman G. Phase I trial of
simultaneous in-field boost with helical tomotherapy for patients with one to three
brain metastases 201; 80(4):1128-33.

[8]

Lagerwaard F, Van der hoorn EA, Verbakel WF, Haasbeek CJ, Slotman BJ, Senan
S. Whole brain radiotherapy with simultaneous integrated boost to multiple brain
metastases using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys
2009; 75(1):253–9.
120

[9]

Hall EJ, Brenner DJ. The radiobiology of radiosurgery: rationale for different
treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys 1993;
25(2):381–5.

[10] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey
J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shanker L, Dodd L, Kaplan R,
Lacombe D, Verweij J. New response evaluation criteria in solid tumors: revised
RECIST guideline (version 1.1). European Journal of Cancer 2009; 45(2):228–47.
[11] Yushkevich PA , Piven J , Hazlett HC, Smith RG, Ho S, Gee JC , Gerig G. Userguided 3D active contour segmentation of anatomical structures: Significantly
improved efficiency and reliability. Neuroimage 2006; 31:1116-28.
[12] Goodman KA, Sneed PK, McDermott MW, Shiau CY, Lamborn KR, Chang S,
Park E, Wara WM, Larson DA. Relationship between pattern of enhancement and
local control of brain metastases after radiosurgery. Int J Radiat Oncol Biol Phys
2001; 50(1), 139–46.
[13] Rodrigues G, Zindler J, Warner A, Lagerwaard F. Recursive partitioning analysis
for the prediction of stereotactic radiosurgery brain metastases lesion control. The
Oncologist 2013; 18(3):330–5.
[14] Conners RW, Harlow CA. A theoretical comparison of texture algorithm. IEEE
Transactions in Pattern Analysis and Machine Learning 1980; 2(3):204–22.
[15] Nieder C, Mehta MP. Prognostic indices for brain metastases--usefulness and
challenges. Radiation Oncology 2009; 4:10.
[16] Sneed PK, Larson DA, Wara WM. Radiotherapy for cerebral metastases.
Neurosurgical Clinics of North America 1996; 7:505-515.
[17] Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA,
Hendrickson FR.. The palliation of brain metastases: Final results of the first two
121

studies by the Radiation Therapy Oncology Group. International Journal of
Radiation Oncology Biology Physics 1980; 6(1): 1-9.
[18] Markesbery WR, Brooks WH, Gupta GD, Young AB. Treatment for patients with
cerebral metastases. Archives of Neurology 1978; 35(11):754-756.
[19] Bauman G, Yartsev S, Fisher B, Kron T, Laperriere N, Heydarian M, VanDyk J.
Simultaneous infield boost with helical tomotherapy for patients with 1 to 3 brain
metastases. American Journal of Clinical Oncology 2007; 30(1):38-44.
[20] Brown JM, Diehn M, Loo B. Stereotactic ablative radiotherapy should be
combined with a hypoxic cell radiosensitizer. International Journal of Radiation
Oncology Biology Physics 2010; 78(2):323–7.
[21] Levegrün S, Pottgen C, Wittig A, Lubcke W, Jawad JA, Stuschke M. International
Journal of Radiation Oncology Biology Physics 2013; 86(4):734–42.
[22] Kondziolka D, Patel A, Lunsford D, Kassam A, Flickinger J. Sterotactic
radiosurgery plus Whole brain radiotherapy versus radiotherapy alone for patients
with multiple brain metastasis, Int. J. Radiation Oncology Biol. Phys 1999;
45(2):427–434.
[23] Wachsberger P, Burd R, Dicker A.Tumor Response to Ionizing Radiation
Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring
Mechanisms of Interaction. Clinical Cancer Research 2003;9:1957-1971.
[24] Deoni SC, Peters TM, and Rutt BK. High-resolution T1 and T2 Mapping of the
Brain in a Clinically acceptable time with DESPOT1 and DESPOT2, Magnetic
Resonance in Medicine 2005; 53: 237-241

122

5

Conclusion and Future Work

This thesis addresses important questions about improving the detection of brain tumor
recurrence following treatment, differentiating glioblastoma from metastasis using
quantitative texture parameters, and improving patient selection for helical tomotherapy
type whole brain radiation therapy with simultaneous infield boost. The main scientific
contributions are summarized below.

5.1

Multiparametric

Imaging

in

Patients

with

Glioblastoma
GBMs are the most malignant form of primary brain tumor where recurrences are
common even after surgery and chemo-radiation therapy1. Discrimination of tumor from
radiation injured tissue is essential for guiding proper surgical and radiotherapy
treatments since tumor recurrences and radiation injury (RI) have similar appearance on
follow-up conventional magnetic resonance imaging2,

3

(MRI). There have been

numerous attempts to differentiate tumor recurrences from RI using various functional
imaging modalities such as CT, MRI, single-photon emission computed tomography and
positron emission tomography, however biopsy is still the gold standard. DTI derived
parameters have been used in an attempt to differentiate tumor16 from radiation injury.
The AxD parameter showed significant differences between the tumor region and RI
region. Other DTI parameters like FA, MD and RD showed no significant differences
between the two regions16.

The majority of the studies that were performed to

differentiate tumor recurrence from RI had no histopathological verification4,5 of the final
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diagnosis and most of these studies were retrospective4,6. A search for an accurate
technique to differentiate tumor from RI continues. As described in Chapter 2 we did not
see significant differences in the diffusion tensor parameters between the two groups.
Instead, we have shown that correlations between diffusion tensor parameters and routine
MRI signal intensities were significant and may be able to differentiate the tumor regions
from radiation injured regions. In this study we used perfusion CT information along with
FLAIR images to separate the tumor regions from radiation injured regions. This was
based on the numerous studies that have successfully correlated perfusion properties of
tumors with histology, and have shown that progressive or recurrent tumors have high
permeability compared to RI regions7,8,9. The correlation of MRI signal intensity values
from FLAIR and diffusion tensor parameters is a novel approach that was tested on a
small group of patients. The preliminary results from this study require further
investigation with a larger patient population to confirm our initial findings and provide
estimates as to the accuracy and diagnostic utility of this new method. In future studies
the tumor regions would need to be confirmed histologically, which is the current gold
standard.

5.2

Texture

Analysis

in

Differentiating

between

Glioblastoma and Metastasis
Glioblastoma and metastasis (MET) are the two most common types of brain tumor and
both these of tumor types exhibit similar radiologic appearance on routine MR imaging10,
124

11

. Differentiating between GBM and MET is very important because they have different

biological mechanisms and require different treatment strategies. Many studies have
focused on advanced imaging modalities12- 14 such as diffusion tensor imaging, perfusion
MRI, spectroscopy, and perfusion CT for non-invasively differentiating between these
two types of tumor. These advanced imaging modalities require long scan times,
expertise in advanced imaging, and additional imaging modalities in the case of CT,
which increases cost, examination time, and patient exposure to radiation. Since T1w
imaging is part of routine brain tumor MRI examination, our technique utilizes easily
accessible MR images and provides quantitative information without additional cost. In
our current study (Chapter 3) we have shown that first-order texture feature of standard
deviation and second-order texture features of entropy, inertia, homogeneity, and energy
may be able to differentiate between the two groups. ROC curve analysis showed
combining first- and second-order features increases the predictive accuracy in
differentiating between GBM and MET. When used individually, the second order
texture feature of inertia had the best predictive accuracy followed by homogeneity and
energy. This study was the first attempt to quantify the texture appearance of the tumor
and use it as an indicator in order to differentiate between GBM and MET. The simplicity
of implementing our technique makes it more desirable than other advanced techniques.
In future studies, various models can be created with combinations of these texture
parameters. With further evaluation and validation of the models on a larger sample size,
these models can be used in clinical settings to predict tumor types with routine MR
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images. This would prevent needless tumor biopsies and cut down the imaging and
ultimately examination time.

5.3

Texture Analysis in Patient Selection for Radiation

Therapy
Helical tomotherapy (HT) is a radiation delivery technique that allows for a radiosurgerytype simultaneous infield boost (SIB) of multiple brain metastases15,

16

synchronously

with whole brain radiation therapy (WBRT) without separate stereotactic procedures.
Patient selection is crucial since some patients’ tumors may not respond to HT type
WBRT+SIB. In our current study (Chapter 4), as a first step toward the broader objective
of developing a means for response prediction, we have demonstrated that smaller size
lesions may respond better to this type of radiation therapy. We have also shown that
measures of appearance provide limited added value for response prediction. Size
measures have also been shown to be a good prognostic factor for the SRS type of
radiation therapy17. Qualitative assessment of the lesions may also predict the success of
the SRS type of radiosurgery18. None of these predictors have previously been studied for
the WBHT + SIB type of radiation therapy. Our study was the first attempt to quantify
the texture appearance of the lesions and use it as an indicator for the prediction of tumor
response to the WBHT + SIB type of radiation therapy. The use of these predictive
markers can help identify the groups of patients who would benefit from WBHT+SIB
(responders) while sparing the non-responders who would not benefit so that the latter
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may be treated with other therapies. For the responders, this type of radiation therapy
may represent an effective and less invasive option compared to the traditional
combinations of surgery, or radiosurgery combined with WBRT. Future work with a
larger sample size will support further validation of our results. This will lead to the
development of a per-lesion prediction of response approach based on pre-treatment
MRI, which will support optimal treatment selection for patients with multiple brain
metastases.
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